1
|
Labrecque Langlais É, Corbin D, Tastet O, Hayek A, Doolub G, Mrad S, Tardif JC, Tanguay JF, Marquis-Gravel G, Tison GH, Kadoury S, Le W, Gallo R, Lesage F, Avram R. Evaluation of stenoses using AI video models applied to coronary angiography. NPJ Digit Med 2024; 7:138. [PMID: 38783037 DOI: 10.1038/s41746-024-01134-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2023] [Accepted: 05/10/2024] [Indexed: 05/25/2024] Open
Abstract
The coronary angiogram is the gold standard for evaluating the severity of coronary artery disease stenoses. Presently, the assessment is conducted visually by cardiologists, a method that lacks standardization. This study introduces DeepCoro, a ground-breaking AI-driven pipeline that integrates advanced vessel tracking and a video-based Swin3D model that was trained and validated on a dataset comprised of 182,418 coronary angiography videos spanning 5 years. DeepCoro achieved a notable precision of 71.89% in identifying coronary artery segments and demonstrated a mean absolute error of 20.15% (95% CI: 19.88-20.40) and a classification AUROC of 0.8294 (95% CI: 0.8215-0.8373) in stenosis percentage prediction compared to traditional cardiologist assessments. When compared to two expert interventional cardiologists, DeepCoro achieved lower variability than the clinical reports (19.09%; 95% CI: 18.55-19.58 vs 21.00%; 95% CI: 20.20-21.76, respectively). In addition, DeepCoro can be fine-tuned to a different modality type. When fine-tuned on quantitative coronary angiography assessments, DeepCoro attained an even lower mean absolute error of 7.75% (95% CI: 7.37-8.07), underscoring the reduced variability inherent to this method. This study establishes DeepCoro as an innovative video-based, adaptable tool in coronary artery disease analysis, significantly enhancing the precision and reliability of stenosis assessment.
Collapse
Affiliation(s)
- Élodie Labrecque Langlais
- Department of Electrical Engineering, Polytechnique Montréal, Montreal, QC, Canada
- Heartwise (heartwise.ai), Montreal Heart Institute, Montreal, QC, Canada
| | - Denis Corbin
- Heartwise (heartwise.ai), Montreal Heart Institute, Montreal, QC, Canada
- Department of Medicine, Montreal Heart Institute, Université de Montréal, Montreal, QC, Canada
| | - Olivier Tastet
- Heartwise (heartwise.ai), Montreal Heart Institute, Montreal, QC, Canada
- Department of Medicine, Montreal Heart Institute, Université de Montréal, Montreal, QC, Canada
| | - Ahmad Hayek
- Department of Medicine, Montreal Heart Institute, Université de Montréal, Montreal, QC, Canada
| | - Gemina Doolub
- Department of Medicine, Montreal Heart Institute, Université de Montréal, Montreal, QC, Canada
| | - Sebastián Mrad
- Department of Medicine, Montreal Heart Institute, Université de Montréal, Montreal, QC, Canada
| | - Jean-Claude Tardif
- Department of Medicine, Montreal Heart Institute, Université de Montréal, Montreal, QC, Canada
| | - Jean-François Tanguay
- Department of Medicine, Montreal Heart Institute, Université de Montréal, Montreal, QC, Canada
| | | | - Geoffrey H Tison
- Department of Medicine, University of California, San Francisco, CA, USA
| | - Samuel Kadoury
- Department of Computer Engineering, Polytechnique Montréal, Montreal, QC, Canada
| | - William Le
- Department of Computer Engineering, Polytechnique Montréal, Montreal, QC, Canada
| | - Richard Gallo
- Department of Medicine, Montreal Heart Institute, Université de Montréal, Montreal, QC, Canada
| | - Frederic Lesage
- Department of Electrical Engineering, Polytechnique Montréal, Montreal, QC, Canada
- Department of Medicine, Montreal Heart Institute, Université de Montréal, Montreal, QC, Canada
| | - Robert Avram
- Heartwise (heartwise.ai), Montreal Heart Institute, Montreal, QC, Canada.
- Department of Medicine, Montreal Heart Institute, Université de Montréal, Montreal, QC, Canada.
| |
Collapse
|
2
|
Patauner F, Gallo R, Durante-Mangoni E, Bertolino L. Monkeypox infection, 18 months later: A vanishing epidemic? Eur J Intern Med 2024; 122:35-37. [PMID: 38369446 DOI: 10.1016/j.ejim.2024.02.017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/03/2024] [Accepted: 02/15/2024] [Indexed: 02/20/2024]
Affiliation(s)
- F Patauner
- Department of Precision Medicine, University of Campania "Luigi Vanvitelli", Via de Crecchio 7, 80138 Napoli Italy; Unit of Infectious & Transplant Medicine, A.O.R.N. Ospedali dei Colli - Ospedale Monaldi, Piazzale Ettore Ruggieri, 80131 Napoli Italy
| | - R Gallo
- Department of Precision Medicine, University of Campania "Luigi Vanvitelli", Via de Crecchio 7, 80138 Napoli Italy; Unit of Infectious & Transplant Medicine, A.O.R.N. Ospedali dei Colli - Ospedale Monaldi, Piazzale Ettore Ruggieri, 80131 Napoli Italy
| | - E Durante-Mangoni
- Department of Precision Medicine, University of Campania "Luigi Vanvitelli", Via de Crecchio 7, 80138 Napoli Italy; Unit of Infectious & Transplant Medicine, A.O.R.N. Ospedali dei Colli - Ospedale Monaldi, Piazzale Ettore Ruggieri, 80131 Napoli Italy.
| | - L Bertolino
- Department of Precision Medicine, University of Campania "Luigi Vanvitelli", Via de Crecchio 7, 80138 Napoli Italy; Unit of Infectious & Transplant Medicine, A.O.R.N. Ospedali dei Colli - Ospedale Monaldi, Piazzale Ettore Ruggieri, 80131 Napoli Italy
| |
Collapse
|
3
|
O’Neill A, Seidman J, Cavagnero K, Li F, Nakatsuji T, Cheng J, Tong Y, Do T, Cau L, Hata T, Modlin R, Gallo R. 349 Functional screening of Cutibacterium acnes isolates reveal determinants of skin inflammation. J Invest Dermatol 2022. [DOI: 10.1016/j.jid.2022.09.362] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
4
|
Khalil S, Williams M, Gallo R. 523 Iron excretion through the epidermis influences host defense against C. albicans. J Invest Dermatol 2022. [DOI: 10.1016/j.jid.2022.05.533] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
5
|
Almoughrabie S, Cau L, Mainzer C, Closs B, Williams K, Bensinger S, Gallo R. 418 Commensal C. acnes promote epidermal keratinocyte lipid synthesis via PPAR. J Invest Dermatol 2022. [DOI: 10.1016/j.jid.2022.05.427] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
6
|
Cavagnero K, Dokoshi T, O'Neill A, Seidman J, Liggins M, Gallo R. 125 Dermal adipocyte precursor immune fibroblastic cells (IFCs) drive neutrophil recruitment in response to bacterial infection. J Invest Dermatol 2022. [DOI: 10.1016/j.jid.2022.05.131] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
7
|
Nakamura Y, Nikhil K, Dokoshi T, Luo E, Wong G, Gallo R. 531 Cardiovascular comorbidities are associated with increased LL37 which promotes the uptake of low-density lipoprotein into macrophages. J Invest Dermatol 2022. [DOI: 10.1016/j.jid.2022.05.541] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
8
|
Beck L, Boguniewicz M, Hata T, Fuxench Z, Simpson E, De Benedetto A, Ko J, Ong P, Yoshida T, Gallo R, Lussier S, David G, Schlievert P, Gill S, Rudman Spergel A, Leung D. 519 Rapid reduction in S. aureus & cytotoxins in dupilumab treated atopic dermatitis subjects. J Invest Dermatol 2022. [DOI: 10.1016/j.jid.2022.05.529] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
9
|
Savio V, Maldini C, Alba P, Saurit V, Berbotto G, Pisoni C, Tissera Y, Nieto R, Maldonado F, Ornella S, Gobbi C, Baños AR, Vivero F, Exeni IE, Cusa A, Bellomio VI, Perez Alamino R, Gomez G, Zelaya D, Risueño F, Quaglia MI, Correa MDLA, Rojas Tessel R, Delavega M, Lazaro MA, Mercé AL, Finucci P, Matellan CE, Romeo C, Martire V, Moyano S, Martin ML, Picco E, Goizueta C, Tralice ER, Tamborenea MN, Subils GC, Gallo R, Pineda Vidal SI, Velasco Zamora JL, Lloves Schenone N, Cosentino V, Rodriguez F, Diaz MP, Viola M, Mamani Ortega ML, Buschiazzo E, Gómez G, Roberts K, Quintana R, Isnardi CA, Pons-Estel G. POS1199 IS PSORIATIC ARTHRITIS A RISK FACTOR FOR SEVERE COVID -19 INFECTION? DATA FROM THE ARGENTINIAN REGISTRY SAR-COVID. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.715] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BackgroundComorbidities, particularly cardio-metabolic disorders, are highly prevalent in patients with psoriatic arthritis (PsA) and they were associated with an increased risk of atherosclerotic cardiovascular disease, which have been associated with higher morbidity and mortality. Whether PsA enhances the risk of SARS-CoV-2 infection or affects the disease outcome remains to be ascertained.ObjectivesTo describe the sociodemographic, clinical and treatment characteristics of patients with PsA with confirmed SARS-CoV-2 infection from the SAR-COVID registry and to identify the variables associated with poor COVID-19 outcomes, comparing them with those with rheumatoid arthritis (RA).MethodsCross-sectional observational study including patients ≥18 years old, with diagnosis of PsA (CASPAR criteria) and RA (ACR / EULAR 2010 criteria), who had confirmed SARS-CoV-2 infection (RT-PCR or serology) from the SAR-COVID registry. Recruitment period was between August 13, 2020 and July 31, 2021. Sociodemographic variables, comorbidities, and treatments were analyzed. To assess the severity of the infection, the ordinal scale of the National Institute of Allergy and Infectious Diseases (NIAID)1 was used, and it was considered that a patient met the primary outcome, if they presented criteria of categories 5 or higher on the severity scale. For this analysis, Chi2 test, Fisher’s test, Student’s test or Wilcoxon test, and binomial logistic regression using NIAID>=5 as dependent variable were performed.ResultsA total of 129 PsA patients and 808 with RA were included. Clinical characteristics are shown in Table 1. Regarding PsA treatment, 12.4% of PsA were receiving IL-17 inhibitors, 5.4% IL12-23 inhibitors, one patient apremilast and one abatacept. The frequency of NIAID≥5 was comparable between groups (PsA 19.5% vs RA 20.1%; p=0.976). (Figure 1).Table 1.Characteristics of patients with PsA and RA who presented COVID-19 in the SAR-COVID registry.Psoriatic arthritis (n=129)Rheumatoid arthritis (n=808)P valueTotal (n=937)Age (years), mean (SD)51.7 (12.7)53.1 (12.9)0.23952.9 (12.9)Female72 (55.8)684 (84.7)<0.001756 (80.7)Comorbidities65 (50.4)355 (43.9)0.203420 (44.8) Obesity (BMI ≥30)19 (15.2)102 (13.4)0.692121 (13.7) Morbid obesity (BMI ≥40)1 (0.8)10 (1.3)111 (1.25) Hypertension35 (28.5)205 (26.8)0.783240 (27.0) Diabetes16 (13.0)67 (8.8)0.18883 (9.39) Dyslipidemia24 (19.5)102 (13.5)0.106126 (14.4) Cardiovascular or cerebrovascular disease5 (11.4)32 (3.9)0.03337 (4.2)Two or more comorbidities55 (42.6)219 (27.1)<0.001274 (29.2)Current smoking4 (3.6)60 (8.4)0.7964 (7.7)High disease activity0 (0)29 (3.8)0.02729 (3.23)Glucocorticoids treatment5 (20.0)95 (60.1)<0.001100 (54.6)Conventional DMARDs47 (36.4)443 (54.8)<0.001490 (52.3)Biologic DMARDs60 (46.5)193 (23.9)<0.001253 (27.0)JAK inhibitors4 (3.10)72 (8.9)0.03876 (8.1)Full recovery of COVID-19105 (84.0)644 (81.7)0.127749 (82.0)COVID-19 complications16 (12.5)68 (8.7)0.22784 (9.2)Death due to COVID-191 (0.8)34 (4.3)0.07435 (3.8)Notes=values n (%) unless otherwise indicated; BMI: Body Mass Index; DMARDs: disease-modifying antirheumatic drugs; JAK inhibitors: Janus kinase inhibitors.PsA patients with NIAID≥5 in comparison with NIAID<5 were older (58.6±11.4 vs 50±12.5; p=0.002), had more frequently hypertension (52.2% vs 23%; p=0.011) and dyslipidemia (39.1% vs 15%; p=0.017). In the multivariate analysis, age (OR 1.06; 95% CI 1.02–1.11) was associated with a worse outcome of the COVID-19 (NIAID≥5) in patients with PsA, while those who received methotrexate (OR 0.34; 95% CI 0.11–0.92) and biological DMARDs (OR 0.28; 95% CI 0.09–0.78) had a better outcome.ConclusionAlthough PsA patients have a higher frequency of cardiovascular and metabolic comorbidities than those with RA, the COVID-19 severity was similar. Most of the patients had mild SARS-CoV-2 infection and a low death rate.References[1]Beigel JH, et al. Remdesivir for the Treatment of Covid-19 - Final Report. N Engl J Med. 2020 Nov 5;383(19):1813-1826.Disclosure of InterestsNone declared
Collapse
|
10
|
Bertoli A, Muñoz L, López Pérez MJ, Sanchez Freytes L, Castaño MS, Saurit V, Berbotto G, Alle G, Severina M, Nieto R, Maldonado F, Pera M, Cogo AK, Baños AR, Vivero F, Pereira DA, Cosatti M, Savio V, Perez Alamino R, Medina MA, Schmid M, Risueño F, Quaglia MI, Pendon GP, Casalla L, Delavega M, Lazaro MA, Finucci P, Morbiducci J, Romeo C, Cucchiaro N, Moyano S, Barbich T, Conti SM, Goizueta C, Tralice ER, Maldini C, Rebak J, Gallo R, Maid P, Velasco Zamora JL, Lloves Schenone N, Porta S, Morales NS, Diaz MP, Viola M, Buschiazzo E, Gómez G, Roberts K, Quintana R, Isnardi CA, Pons-Estel G, Matellan CE. POS1200 DIFFERENCES BETWEEN THE FIRST AND THE SECOND WAVE OF SARS-COV-2 INFECTION IN PATIENTS WITH IMMUNE-MEDIATED INFLAMMATORY DISEASES IN ARGENTINA: DATA FROM THE SAR-COVID REGISTRY. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.776] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BackgroundIn Argentina we have witnessed two COVID 19 waves between 2020 and 2021. The first wave occurred during the spring of 2020 and it was related to the wild type of the virus, the second occurred during the fall/winter of 2021 when the gamma variant showed a clear predominance. During the first wave, patient with rheumatic diseases showed a higher frequency of hospitalization and mortality (4% vs 0.26%) when compared to the general population1; at that time, however, vaccination was not yet available.ObjectivesTo compare sociodemographic and disease characteristics, course and outcomes of SARS-CoV-2 infection in patients with immune-mediated/autoinflammatory diseases (IMADs) during the first and second waves in Argentina.MethodsSAR-COVID is a national, multicenter, longitudinal and observational registry, in which patients ≥18 years of age, with a diagnosis of a rheumatic disease who had confirmed SARS-CoV-2 infection (RT-PCR or positive serology) were consecutively included since August 2020. For the purpose of this report, only patients with IMADs who had SARS-CoV-2 infection during the first wave (defined as cases occurred between March 2020 and March 2021) and the second wave (cases occurred between April and August 2021) were examined. Sociodemographic characteristics, disease diagnosis and activity, comorbidities, immunosuppressive treatment and COVID 19 clinical characteristics, complications and outcomes: hospitalization, intensive care unit (ICU) admission, use of mechanical ventilation and death were compared among groups. Descriptive statistical analysis was performed. Variables were compared with Chi squared test and Student T test or Mann Whitney test. Multivariable logistic regression models with forward and backward selection method, using hospitalization, ICU admission and death as dependent variables were carried out.ResultsA total of 1777 patients were included, 1342 from the first wave and 435 of the second one. Patients had a mean (SD) age of 50.7 (14.2) years and 81% were female. Both groups of patients were similar in terms of socio-demographic features, disease diagnosis, disease activity, the use of glucocorticoids ≥ 10 mg/day and the immunosuppressive drugs (Table 1 below). Patients infected during the first wave have higher frequency of comorbidities (49% vs 41%; p= 0.004). Hospitalizations due to COVID 19 (31% vs 20%; p <0.001) and ICU admissions (9% vs 5%; p= 0.009) were higher during the first wave. No differences in the use of mechanical ventilation (16% vs 16%; p= 0.97) nor in the mortality rate (5% vs 4%; p= 0.41) were observed. In the multivariable analysis, after adjusting for demographics, clinical features and immunosuppressive treatment, patients infected during the second wave were 40% less likely to be hospitalized (OR= 0.6, IC95% 0.4-0.8) and to be admitted to the ICU (OR= 0.6, IC95% 0.3-0.9).Table 1.Variable (% or Mean – SD)First wave(n=1342)Second wave(n=435)p ValueFemale gender81800.7Age (years)51.0 (14.5)50.0 (13.3)0.2Disease diagnosis Rheumatoid arthritis46461 Ankylosing spondylitis10110.8 Systemic lupus erythematosus171850.9 Systemic Scleroderma551 Sjögren´s syndrome650.7 Inflammatory myopathies330.5 Vasculitis430.4Disease activity High430.5Use of immune modulatorsDMARDcs53560.2DMARDts460.1DMARDb82821Use of glucocorticoids ≥10 mg12120.9Comorbidities49410.004ConclusionThe impact of COVID 19 in Argentina, in terms of mortality in patients with IMADs was still higher compared to the general population during the second wave. However, the frequency of hospitalizations and ICU admissions was lower. These findings could be explained by the introduction of the SARS COV 2 vaccination and, probably, by the cumulative knowledge and management improvement of this infection among physicians.References[1]Isnardi CA et al. Epidemiology and outcomes of patients with rheumatic diseases and SARS-COV-2 infection: data from the argentinean SAR-COVID Registry. Ann Rheum Dis, 2021, suppl 1, 887.Disclosure of InterestsNone declared
Collapse
|
11
|
Tramontano G, Tomatis V, Gilio M, Giusti A, Giarracca F, Gallo R, Bandi L, Bianchi G. AB1211 DOES BODY MASS INDEX AND METABOLIC SYNDROME IMPACT ON FIBROMYALGIA? Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.4834] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
BackgroundFibromyalgia (FBM), obesity and the metabolic syndrome (MTB) are common conditions with significant impact on health and quality of life, producing relevant economic burden for healthcare systems. Although obesity represents a negative prognostic factor for FBM, the relation between body mass index (BMI) or MTB and FBM severity is still unclear.ObjectivesThe aim of our ongoing study was to evaluate the relationship between BMI or prevalent MTB and FBM severity, estimated with 3 different severity scores.MethodsWe included the first 100 women presenting with FBM, defined according to the ACR2016 diagnostic criteria, consecutively evaluated during the period of 1 year in 2 Clinic in Italy. On enrolment were assessed/recorded demographic, clinical and pharmacological characteristics, weight, height, physical activity, tenderness, pain and symptoms. The following scores were calculated: tender points count (TP), Widespread Pain Index (WPI), Polysymptomatic Distress Scale (PDS), Fibromyalgia Impact Questionnaire (FIQ) and modified Fibromyalgia Assessment Status (mFAS). BMI was calculated, and the presence of MTB was evaluated according to current definition. Patients were categorized as presenting with severe disease or moderate/mild disease according to recent definition validated in an Italian population. The prevalence of MTB and the mean ± standard deviation (SD) BMI in subgroups defined according to severity were estimated.ResultsMean age ±SD was 57.5±12.7 years, mean BMI ±SD was 25.3±5.1, and 9.5% presented with MTB. FBM severity (mean±SD) calculated by PDS, FIQ and mFAS was respectively 25.3±9.3, 63.2±23.1, and 30.1±7.7. Patients with the highest FBM severity according to PDS (>25) were less likely to present with MTB (2.4%) compared to those with a PDS of 0-25 (20.0%, P=.026), with an adjusted (age and BMI) OR (95%CI) for presenting with MTB in patients with less severe FBM of 8.2 (0.962-69.925, P=.054). Similar results were found when the specific conditions characterizing the MTB were considered separately, except for excessive body fat around the waist (not related to severity). The BMI ±SD was comparable between patients with severe disease (25.8±5.8) according to PDS and those with less severe FBM (24.8±4.4, P=.388), with no correlation between BMI and PDS (Rho: 0.083, P=.454). Considering all other characteristics of the two groups defined according to PDS categories (PDS >25 versus PDS 0-25) a significant difference was found in mean age ±SD, greater in patients with less severe FBM (60.2±13.2) compared to those with highest FBM severity (54.8±11.6, P=.046). Similar but less significant findings were found also with FIQ and mFAS. The prevalence of MTB according to the FIQ was 7.3% for highest severity versus 14.3% for less severe FBM (P=.200), with a comparable BMI ±SD between the two groups (respectively 26.2±6.1 versus 24.4±3.7, P=.125). Corresponding figures for MTB or BMI and FBM severity according to the mFAS were respectively: prevalence of MTB in highest severity 3.0% versus 16.3% in the less severe FBM (P=.078); mean ±SD BMI in highest severity 26.4±6.2 versus 24.6±4.2 in less severe patients (P=.121).ConclusionThe preliminary results of our ongoing analysis demonstrated a slightly inverse relationship between FBM severity and the prevalence of MTB, trending to significance, while no relationship was found between severity and BMI.References[1]Salaffi F. Fibromyalgia Criteria and Severity Scales for Clinical and Epidemiological Studies: A Modification of the ACR Preliminary Diagnostic Criteria for Fibromyalgia. Rheumatology. Volume 60, Issue 2, February 2021, Pages 728–736,[2]Migliorini F. BMI but not age and sex negatively impact on the outcome of pharmacotherapy in fibromyalgia: a systematic review. Expert Rev Clin Pharmacol. 2021 Aug;14:1029-1038.[3]D’Onghia M. Fibromyalgia and obesity: A comprehensive systematic review and meta-analysis. Semin Arthritis Rheum. 2021 Apr;51:409-424.[4]Aparicio VA. Fibromyalgia’s key symptoms in normal-weight, overweight, and obese female patients. Pain Manag Nurs. 2013 Dec;14:268-276.Disclosure of InterestsNone declared
Collapse
|
12
|
Langlais ÉL, Thériault-Lauzier P, Marquis-Gravel G, Kulbay M, So DY, Tanguay JF, Ly HQ, Gallo R, Lesage F, Avram R. Novel Artificial Intelligence Applications in Cardiology: Current Landscape, Limitations, and the Road to Real-World Applications. J Cardiovasc Transl Res 2022:10.1007/s12265-022-10260-x. [PMID: 35460017 DOI: 10.1007/s12265-022-10260-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/21/2022] [Accepted: 04/11/2022] [Indexed: 11/25/2022]
Abstract
Cardiovascular diseases are the leading cause of death globally and contribute significantly to the cost of healthcare. Artificial intelligence (AI) is poised to reshape cardiology. Using supervised and unsupervised learning, the two main branches of AI, several applications have been developed in recent years to improve risk prediction, allow large-scale analysis of medical data, and phenotype patients for personalized medicine. In this review, we examine the key advances in AI in cardiology and its limitations regarding bias in the data, standardization in reporting, data access, and model trust and accountability in cases of error. Finally, we discuss implementation methods to unleash AI's potential in making healthcare more accurate and efficient. Several steps need to be followed and challenges overcome in order to successfully integrate AI in clinical practice and ensure its longevity.
Collapse
Affiliation(s)
- Élodie Labrecque Langlais
- Division of Cardiology, Department of Medicine, Montreal Heart Institute, University of Montreal, 5000 Belanger Street, Montreal, QC, H1T 1C8, Canada
- Biomedical Engineering, École Polytechnique de Montréal, 2500 Chemin de Polytechnique, Montreal, QC, H3T 1J4, Canada
| | - Pascal Thériault-Lauzier
- Division of Cardiology, Department of Medicine, University of Ottawa Heart Institute, University of Ottawa, 40 Ruskin Street, Ottawa, ON, K1Y 4W7, Canada
| | - Guillaume Marquis-Gravel
- Division of Cardiology, Department of Medicine, Montreal Heart Institute, University of Montreal, 5000 Belanger Street, Montreal, QC, H1T 1C8, Canada
- Department of Medicine, University of Montreal, 2900 Edouard Montpetit Blvd, Montreal, QC, H3T 1J4, Canada
| | - Merve Kulbay
- Department of Medicine, University of Montreal, 2900 Edouard Montpetit Blvd, Montreal, QC, H3T 1J4, Canada
| | - Derek Y So
- Division of Cardiology, Department of Medicine, University of Ottawa Heart Institute, University of Ottawa, 40 Ruskin Street, Ottawa, ON, K1Y 4W7, Canada
| | - Jean-François Tanguay
- Division of Cardiology, Department of Medicine, Montreal Heart Institute, University of Montreal, 5000 Belanger Street, Montreal, QC, H1T 1C8, Canada
| | - Hung Q Ly
- Division of Cardiology, Department of Medicine, Montreal Heart Institute, University of Montreal, 5000 Belanger Street, Montreal, QC, H1T 1C8, Canada
| | - Richard Gallo
- Division of Cardiology, Department of Medicine, Montreal Heart Institute, University of Montreal, 5000 Belanger Street, Montreal, QC, H1T 1C8, Canada
- Department of Medicine, University of Montreal, 2900 Edouard Montpetit Blvd, Montreal, QC, H3T 1J4, Canada
| | - Frédéric Lesage
- Division of Cardiology, Department of Medicine, Montreal Heart Institute, University of Montreal, 5000 Belanger Street, Montreal, QC, H1T 1C8, Canada
- Biomedical Engineering, École Polytechnique de Montréal, 2500 Chemin de Polytechnique, Montreal, QC, H3T 1J4, Canada
| | - Robert Avram
- Division of Cardiology, Department of Medicine, Montreal Heart Institute, University of Montreal, 5000 Belanger Street, Montreal, QC, H1T 1C8, Canada.
- Department of Medicine, University of Montreal, 2900 Edouard Montpetit Blvd, Montreal, QC, H3T 1J4, Canada.
| |
Collapse
|
13
|
Beck L, Boguniewicz M, Hata T, Fuxench Z, Simpson E, De Benedetto A, Ko J, Ong P, Yoshida T, Gallo R, Brar K, Schlievert P, Villareal M, Lussier S, David G, Rudman-Spergel A, Leung D. Effect of Dupilumab on the Host-Microbe Interface in Atopic Dermatitis. J Allergy Clin Immunol 2022. [DOI: 10.1016/j.jaci.2021.12.503] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
14
|
Massart N, Maxime V, Fillatre P, Razazi K, Ferré A, Moine P, Legay F, Voiriot G, Amara M, Santi F, Nseir S, Marque-Juillet S, Bounab R, Barbarot N, Bruneel F, Luyt CE, Pham T, Pavot A, Monnet X, Richard C, Demoule A, Dres M, Mayaux J, Beurton A, Daubin C, Descamps R, Joret A, Du Cheyron D, Pene F, Chiche JD, Jozwiak M, Jaubert P, Voiriot G, Fartoukh M, Teulier M, Blayau C, Bodenes L, Ferriere N, Auchabie J, Le Meur A, Pignal S, Mazzoni T, Quenot JP, Andreu P, Roudau JB, Labruyère M, Nseir S, Preau S, Poissy J, Mathieu D, Benhamida S, Paulet R, Roucaud N, Thyrault M, Daviet F, Hraiech S, Parzy G, Sylvestre A, Jochmans S, Bouilland AL, Monchi M, Déserts MDD, Mathais Q, Rager G, Pasquier P, Reignier J, Seguin A, Garret C, Canet E, Dellamonica J, Saccheri C, Lombardi R, Kouchit Y, Jacquier S, Mathonnet A, Nay MA, Runge I, Martino F, Flurin L, Rolle A, Carles M, Coudroy R, Thille AW, Frat JP, Rodriguez M, Beuret P, Tientcheu A, Vincent A, Michelin F, Tamion F, Carpentier D, Boyer D, Girault C, Gissot V, Ehrmann S, Gandonniere CS, Elaroussi D, Delbove A, Fedun Y, Huntzinger J, Lebas E, Kisoka G, Grégoire C, Marchetta S, Lambermont B, Argaud L, Baudry T, Bertrand PJ, Dargent A, Guitton C, Chudeau N, Landais M, Darreau C, Ferre A, Gros A, Lacave G, Bruneel F, Neuville M, JérômeDevaquet, Tachon G, Gallo R, Chelha R, Galbois A, Jallot A, Lemoine LC, Kuteifan K, Pointurier V, Jandeaux LM, Mootien J, Damoisel C, Sztrymf B, Schmidt M, Combes A, Chommeloux J, Luyt CE, Schortgen F, Rusel L, Jung C, Gobert F, Vimpere D, Lamhaut L, Sauneuf B, Charrrier L, Calus J, Desmeules I, Painvin B, Tadie JM, Castelain V, Michard B, Herbrecht JE, Baldacini M, Weiss N, Demeret S, Marois C, Rohaut B, Moury PH, Savida AC, Couadau E, Série M, Alexandru N, Bruel C, Fontaine C, Garrigou S, Mahler JC, Leclerc M, Ramakers M, Garçon P, Massou N, Van Vong L, Sen J, Lucas N, Chemouni F, Stoclin A, Avenel A, Faure H, Gentilhomme A, Ricome S, Abraham P, Monard C, Textoris J, Rimmele T, Montini F, Lejour G, Lazard T, Etienney I, Kerroumi Y, Dupuis C, Bereiziat M, Coupez E, Thouy F, Hoffmann C, Donat N, Chrisment A, Blot RM, Kimmoun A, Jacquot A, Mattei M, Levy B, Ravan R, Dopeux L, Liteaudon JM, Roux D, Rey B, Anghel R, Schenesse D, Gevrey V, Castanera J, Petua P, Madeux B, Hartman O, Piagnerelli M, Joosten A, Noel C, Biston P, Noel T, Bouar GLE, Boukhanza M, Demarest E, Bajolet MF, Charrier N, Quenet A, Zylberfajn C, Dufour N, Mégarbane B, Voicu S, Deye N, Malissin I, Legay F, Debarre M, Barbarot N, Fillatre P, Delord B, Laterrade T, Saghi T, Pujol W, Cungi PJ, Esnault P, Cardinale M, Ha VHT, Fleury G, Brou MA, Zafimahazo D, Tran-Van D, Avargues P, Carenco L, Robin N, Ouali A, Houdou L, Le Terrier C, Suh N, Primmaz S, Pugin J, Weiss E, Gauss T, Moyer JD, Burtz CP, La Combe B, Smonig R, Violleau J, Cailliez P, Chelly J, Marchalot A, Saladin C, Bigot C, Fayolle PM, Fatséas J, Ibrahim A, Resiere D, Hage R, Cholet C, Cantier M, Trouiler P, Montravers P, Lortat-Jacob B, Tanaka S, Dinh AT, Duranteau J, Harrois A, Dubreuil G, Werner M, Godier A, Hamada S, Zlotnik D, Nougue H, Mekontso-Dessap A, Carteaux G, Razazi K, De Prost N, Mongardon N, Lamraoui M, Alessandri C, de Roux Q, de Roquetaillade C, Chousterman BG, Mebazaa A, Gayat E, Garnier M, Pardo E, LeaSatre-Buisson, Gutton C, Yvin E, Marcault C, Azoulay E, Darmon M, Oufella HA, Hariri G, Urbina T, Mazerand S, Heming N, Santi F, Moine P, Annane D, Bouglé A, Omar E, Lancelot A, Begot E, Plantefeve G, Contou D, Mentec H, Pajot O, Faguer S, Cointault O, Lavayssiere L, Nogier MB, Jamme M, Pichereau C, Hayon J, Outin H, Dépret F, Coutrot M, Chaussard M, Guillemet L, Goffin P, Thouny R, Guntz J, Jadot L, Persichini R, Jean-Michel V, Georges H, Caulier T, Pradel G, Hausermann MH, Nguyen-Valat TMH, Boudinaud M, Vivier E, SylvèneRosseli, Bourdin G, Pommier C, Vinclair M, Poignant S, Mons S, Bougouin W, Bruna F, Maestraggi Q, Roth C, Bitker L, Dhelft F, Bonnet-Chateau J, Filippelli M, Morichau-Beauchant T, Thierry S, Le Roy C, Jouan MS, Goncalves B, Mazeraud A, Daniel M, Sharshar T, Cadoz C, RostaneGaci, Gette S, Louis G, Sacleux SC, Ordan MA, Cravoisy A, Conrad M, Courte G, Gibot S, Benzidi Y, Casella C, Serpin L, Setti JL, Besse MC, Bourreau A, Pillot J, Rivera C, Vinclair C, Robaux MA, Achino C, Delignette MC, Mazard T, Aubrun F, Bouchet B, Frérou A, Muller L, Quentin C, Degoul S, Stihle X, Sumian C, Bergero N, Lanaspre B, Quintard H, Maiziere EM, Egreteau PY, Leloup G, Berteau F, Cottrel M, Bouteloup M, Jeannot M, Blanc Q, Saison J, Geneau I, Grenot R, Ouchike A, Hazera P, Masse AL, Demiri S, Vezinet C, Baron E, Benchetrit D, Monsel A, Trebbia G, Schaack E, Lepecq R, Bobet M, Vinsonneau C, Dekeyser T, Delforge Q, Rahmani I, Vivet B, Paillot J, Hierle L, Chaignat C, Valette S, Her B, Brunet J, Page M, Boiste F, Collin A, Bavozet F, Garin A, Dlala M, KaisMhamdi, Beilouny B, Lavalard A, Perez S, Veber B, Guitard PG, Gouin P, Lamacz A, Plouvier F, Delaborde BP, Kherchache A, Chaalal A, Ricard JD, Amouretti M, Freita-Ramos S, Roux D, Constantin JM, Assefi M, Lecore M, Selves A, Prevost F, Lamer C, Shi R, Knani L, Floury SP, Vettoretti L, Levy M, Marsac L, Dauger S, Guilmin-Crépon S, Winiszewski H, Piton G, Soumagne T, Capellier G, Putegnat JB, Bayle F, Perrou M, Thao G, Géri G, Charron C, Repessé X, Vieillard-Baron A, Guilbart M, Roger PA, Hinard S, Macq PY, Chaulier K, Goutte S, Chillet P, Pitta A, Darjent B, Bruneau A, Lasocki S, Leger M, Gergaud S, Lemarie P, Terzi N, Schwebel C, Dartevel A, Galerneau LM, Diehl JL, Hauw-Berlemont C, Péron N, Guérot E, Amoli AM, Benhamou M, Deyme JP, Andremont O, Lena D, Cady J, Causeret A, De La Chapelle A, Cracco C, Rouleau S, Schnell D, Foucault C, Lory C, Chapelle T, Bruckert V, Garcia J, Sahraoui A, Abbosh N, Bornstain C, Pernet P, Poirson F, Pasem A, Karoubi P, Poupinel V, Gauthier C, Bouniol F, Feuchere P, Heron A, Carreira S, Emery M, Le Floch AS, Giovannangeli L, Herzog N, Giacardi C, Baudic T, Thill C, Lebbah S, Palmyre J, Tubach F, Hajage D, Bonnet N, Ebstein N, Gaudry S, Cohen Y, Noublanche J, Lesieur O, Sément A, Roca-Cerezo I, Pascal M, Sma N, Colin G, Lacherade JC, Bionz G, Maquigneau N, Bouzat P, Durand M, Hérault MC, Payen JF. Correction to: Characteristics and prognosis of bloodstream infection in patients with COVID‑19 admitted in the ICU: an ancillary study of the COVID‑ICU study. Ann Intensive Care 2022; 12:4. [PMID: 35015163 PMCID: PMC8748185 DOI: 10.1186/s13613-022-00979-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
15
|
Reyes AA, Alle G, Tanten R, Scolnik M, Soriano E, Berbotto G, Haye M, Gamba MJ, Nieto R, García M, Savio V, Gonzalez Lucero L, Alba P, Takashima L, Risueño F, Casalla L, Cucchiaro N, Bertoli A, Porta S, Maldini C, Gallo R, Goizueta C, Picco E, Quintana R, Roberts K, Isnardi CA, Pons-Estel G. POS1188 COVID-19 IN PATIENTS WITH RHEUMATIC DISEASES: COMPARISON OF DATA FROM THE ARGENTINE REGISTRY (SAR-COVID), WITH THE LATIN AMERICAN AND GLOBAL REGISTRY (GLOBAL RHEUMATOLOGY ALLIANCE). Ann Rheum Dis 2021. [DOI: 10.1136/annrheumdis-2021-eular.1458] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Background:SARS CoV-2 infection has recently burst onto the global scene, and the knowledge of the course of this infection in patients with rheumatic diseases receiving immunomodulatory treatment is still insufficient. The Argentine Society of Rheumatology (SAR) designed a national registry called SAR-COVID in order to get to assess our reality.Objectives:To identify the particular characteristics of patients with rheumatic diseases and COVID-19 in Argentina (SAR-COVID Registry), and to compare them with the data reported at the Latin American and Global level (Global International Alliance Rheum-COVID Registry).Methods:A national, multicenter, prospective and observational registry was carried out. Patients older than 18 years, with a diagnosis of rheumatic disease and SARS-CoV-2 infection by PCR or serology, were included between August 13, 2020 and January 17, 2021. Demographic data, underlying rheumatic disease (activity of the disease, current treatment), comorbidities, clinical-laboratory characteristics of the SARS-CoV-2 infection, as well as received treatments (pharmacological, oxygen therapy / ventilatory support) and outcomes (hospitalization, mortality) were recorded. The characteristics of the included patients were compared with the data reported at the Latin American and global level. Descriptive statistics were performed. Comparisons between groups were made using ANOVA, chi2 or Fisher’s test, according to the type of variable.Results:Four hundred sixty-five patients from Argentina, 74 patients from Latin America and 583 from the rest of the world were included, mostly women (79.6%, 73% and 71% respectively), with a mean age of 50.2 (SD 15.3), 53.5 (DE 15.6) and 55.8 (15.5), years respectively. The most frequent rheumatic diseases in the three groups were rheumatoid arthritis (43.9%, 35%, and 39%) and systemic lupus erythematosus (16.1%, 22%, and 14%) (Table 1).In Argentina, fewer patients received specific pharmacological treatment for COVID-19 (40.9%, 68% and 43% respectively, p <0.0001), and there was a lower requirement of NIMV / IMV (Non-Invasive Mechanical Ventilation/Invasive Mechanical Ventilation) than in the rest of Latin America and the world (10.5% vs 31% vs 13%, p <0.0001).Hospitalization was lower in Argentina than in the rest of Latin America (37.4% vs 61% p 0.0002) and of the world (37.4% vs 45% p 0.0123), and mortality was numerically lower in Argentina, but without statistically significant differences between the three groups (6.9%, 12% and 11%; p 0.6311). Most of the patients, (86.9%) did not present any complications in Argentina, with a statistically significant difference with the rest of the groups (62% and 77%, p <0.0001) (Graph 1).Conclusion:The patients with rheumatic diseases and SARS-CoV-2 infection reported in this argentinian registry received less specific pharmacological treatment for COVID-19, presented fewer complications and required less ventilatory support, than those reported in the Latinoamerican and Global registry. However, no statistically significant differences were observed in terms of mortality.Graph 1.Main outcomes and evolution of patients with rheumatic disease and COVID-19.References:[1]Stokes, Erin K, Zambrano, Laura D, Anderson, Kayla N, et al. Coronavirus Disease 2019 Case Surveillance - United States, January 22-May 30, 2020. MMWR Morb Mortal Wkly Rep; 69(24): 759-765, 2020 Jun 19.[2]Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm síndromes and immunosuppression. Lancet 2020;395:1033–4.[3]Gianfrancesco M, et al. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis 2020;79:859–866.[4]Manuel F. Ugarte-Gil, et al. Characteristics associated with Covid-19 in patients with Rheumatic Disease in Latin America. Global Rheumatology. Septiembre 2020.Disclosure of Interests:Alvaro Andres Reyes Grant/research support from: “Unrestricted grants: Pfizer, Abbvie, Elea Phoenix. None of them have access to patient data.”, Gelsomina Alle Grant/research support from: “Unrestricted grants: Pfizer, Abbvie, Elea Phoenix. None of them have access to patient data.”, Romina Tanten Grant/research support from: “Unrestricted grants: Pfizer, Abbvie, Elea Phoenix. None of them have access to patient data.”, Marina Scolnik Grant/research support from: “Unrestricted grants: Pfizer, Abbvie, Elea Phoenix. None of them have access to patient data.”, Enrique Soriano Grant/research support from: “Unrestricted grants: Pfizer, Abbvie, Elea Phoenix. None of them have access to patient data.”, Guillermo Berbotto Grant/research support from: “Unrestricted grants: Pfizer, Abbvie, Elea Phoenix. None of them have access to patient data.”, Maria Haye Grant/research support from: “Unrestricted grants: Pfizer, Abbvie, Elea Phoenix. None of them have access to patient data.”, María Julieta Gamba Grant/research support from: “Unrestricted grants: Pfizer, Abbvie, Elea Phoenix. None of them have access to patient data.”, Romina Nieto Grant/research support from: “Unrestricted grants: Pfizer, Abbvie, Elea Phoenix. None of them have access to patient data.”, Mercedes García Grant/research support from: “Unrestricted grants: Pfizer, Abbvie, Elea Phoenix. None of them have access to patient data.”, Veronica Savio Grant/research support from: “Unrestricted grants: Pfizer, Abbvie, Elea Phoenix. None of them have access to patient data.”, Luciana Gonzalez Lucero Grant/research support from: “Unrestricted grants: Pfizer, Abbvie, Elea Phoenix. None of them have access to patient data.”, Paula Alba Grant/research support from: “Unrestricted grants: Pfizer, Abbvie, Elea Phoenix. None of them have access to patient data.”, Lorena Takashima Grant/research support from: “Unrestricted grants: Pfizer, Abbvie, Elea Phoenix. None of them have access to patient data.”, FABIAN RISUEÑO Grant/research support from: “Unrestricted grants: Pfizer, Abbvie, Elea Phoenix. None of them have access to patient data.”, Luciana CASALLA Grant/research support from: “Unrestricted grants: Pfizer, Abbvie, Elea Phoenix. None of them have access to patient data.”, Natalia Cucchiaro Grant/research support from: “Unrestricted grants: Pfizer, Abbvie, Elea Phoenix. None of them have access to patient data.”, Ana Bertoli Grant/research support from: “Unrestricted grants: Pfizer, Abbvie, Elea Phoenix. None of them have access to patient data.”, Sabrina POrta Grant/research support from: “Unrestricted grants: Pfizer, Abbvie, Elea Phoenix. None of them have access to patient data.”, Carla Maldini Grant/research support from: “Unrestricted grants: Pfizer, Abbvie, Elea Phoenix. None of them have access to patient data.”, Rosana Gallo Grant/research support from: “Unrestricted grants: Pfizer, Abbvie, Elea Phoenix. None of them have access to patient data.”, Cecilia Goizueta Grant/research support from: “Unrestricted grants: Pfizer, Abbvie, Elea Phoenix. None of them have access to patient data.”, Eugenia Picco Grant/research support from: “Unrestricted grants: Pfizer, Abbvie, Elea Phoenix. None of them have access to patient data.”, Rosana Quintana Grant/research support from: “Unrestricted grants: Pfizer, Abbvie, Elea Phoenix. None of them have access to patient data.”, Karen Roberts Grant/research support from: “Unrestricted grants: Pfizer, Abbvie, Elea Phoenix. None of them have access to patient data.”, Carolina Ayelen Isnardi Grant/research support from: “Unrestricted grants: Pfizer, Abbvie, Elea Phoenix. None of them have access to patient data.”, Guillermo Pons-Estel Grant/research support from: “Unrestricted grants: Pfizer, Abbvie, Elea Phoenix. None of them have access to patient data.”
Collapse
|
16
|
Liggins M, O'Neill A, Li F, Seidman J, Chang J, Shafiq F, Hatta T, Gallo R. 215 Reactive adipogenesis in the perifollicular stroma is a component of the host immune response in acne. J Invest Dermatol 2021. [DOI: 10.1016/j.jid.2021.02.236] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
17
|
Beck L, Boguniewicz M, Hatta T, Chiesa Fuxench Z, Simpson E, De Benedetto A, Ko J, Ong P, Yoshida T, Gallo R, Schlievert P, Gill S, Mosmann T, Berdyshev E, David G, Lussier S, Rudman Spergel A, Leung D. 666 Effect of dupilumab on the host-microbe interface in atopic dermatitis. J Invest Dermatol 2021. [DOI: 10.1016/j.jid.2021.02.696] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
18
|
Gallo R, Minardi V, Contoli B, Possenti V, Carrozzi G, Trinito MO, Ramigni M, Fateh-Moghadam P, Masocco M, D’Andrea E. Flu vaccination among health workers in Italy: results from the nationwide surveillance PASSI 2015-18. Eur J Public Health 2020. [DOI: 10.1093/eurpub/ckaa165.1095] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Influenza causes a significant health and socio-economic burden every year. Healthcare workers (HCWs) are at higher risk of exposure to respiratory pathogens than general population, including seasonal influenza virus, with potential threats to their health and patients' safety. We aimed to estimate the adherence to flu vaccination of health workers in 2015-2018 seasons in Italy.
Methods
We analyzed data collected between 2015 and 2018 from the Italian Behavioral Risk Factor Surveillance System (PASSI). PASSI collects data on health behaviors in the adults (18-64 years) through telephonic administration of standardized questionnaires to a representative sample of Italian population. The answers related to flu vaccination refer to the vaccination campaign preceding the interview
Results
Preliminary data show that overall 11.9% (CI 10.3% - 13.7%) of HCWs reported to have been vaccinated vs 7.2% (CI 6.9% - 7.5%) of the total population sample. Physicians showed a higher overall adherence compared to other healthcare professionals (22.4% [CI 18% - 27.5%] vs 9% [CI 7.4% - 10.9%], respectively). Differences of adherence were found also across age groups: 18.3% [CI 15% - 22.2%] of respondents between 50-64 years reported to have received a vaccination compared to 10% (CI 7.9% - 12.5%) and 4.3% (CI 2.8% - 6.4%) of 35-49 years and 18-34 years age groups, respectively. The annual influenza vaccination coverage for people working in healthcare has increased over the years (9.8% in 2015 vs 14.1% in 2018).
Conclusions
Although coverage rates are increasing over time, adherence to influenza vaccination is still too low, especially among younger HCWs and non-medical HCWs. Strategic actions, such as local and national programs to increase self-awareness of being an at-high-risk category for contracting and transmitting infections and/or mandatory vaccination, should be adopted to sharply achieve an optimal coverage rate for HCWs.
Key messages
Adherence to seasonal influenza vaccination is still very low among Italian HCWs. A participatory attitude towards vaccination for HCWs should be pursued. Monitoring and reporting process should be improved to provide further detailed evidence for adopting targeted programs.
Collapse
Affiliation(s)
- R Gallo
- Department of Prevention, Local Health Unit Turin City, Turin, Italy
| | - V Minardi
- National Centre for Disease Prevention and Health Promotion, Italian National Institute of Health, Rome, Italy
| | - B Contoli
- National Centre for Disease Prevention and Health Promotion, Italian National Institute of Health, Rome, Italy
| | - V Possenti
- National Centre for Disease Prevention and Health Promotion, Italian National Institute of Health, Rome, Italy
| | - G Carrozzi
- Department of Public Health, Local Health Unit Modena, Modena, Italy
| | - M O Trinito
- Department of Prevention, Local Health Unit Roma 2, Rome, Italy
| | - M Ramigni
- Department of Epidemiology, Local Health Unit 2 Marca Trevigiana, Treviso, Italy
| | - P Fateh-Moghadam
- Health Education Service, Provincial Agency for Health Services, Trento, Italy
| | - M Masocco
- National Centre for Disease Prevention and Health Promotion, Italian National Institute of Health, Rome, Italy
| | - E D’Andrea
- Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Harvard Medical School, Boston, USA
- Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy
| |
Collapse
|
19
|
Fargnoli MC, Esposito M, Ferrucci S, Girolomoni G, Offidani A, Patrizi A, Peris K, Costanzo A, Malara G, Pellacani G, Romanelli M, Amerio P, Cristaudo A, Flori ML, Motolese A, Betto P, Patruno C, Pigatto P, Peccianti C, Stinco G, Zalaudek I, Bianchi L, Boccaletti V, Cannavo SP, Cusano F, Lembo S, Mozzillo R, Gallo R, Potenza C, Rongioletti F, Tiberio R, Grieco T, Micali G, Persechino S, Pettinato M, Pucci S, Stingeni L, Caruso C, Argenziano G. A 48-week update of a multicentre real-life experience of dupilumab in adult patients with moderate-to-severe atopic dermatitis. J DERMATOL TREAT 2020; 33:1146-1149. [DOI: 10.1080/09546634.2020.1773379] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Affiliation(s)
- M. C. Fargnoli
- Dermatology, Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila, L’Aquila, Italy
| | - M. Esposito
- Dermatology, Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila, L’Aquila, Italy
| | - S. Ferrucci
- Unit of Dermatology, Fondazione IRCCS Ca’ Grande Ospedale Maggiore Policlinico, Milan, Italy
| | - G. Girolomoni
- Section of Dermatology and Venereology, Department of Medicine, University of Verona, Verona, Italy
| | - A. Offidani
- Dermatology Unit, Department of Clinical and Molecular Sciences, Polytechnic Marche University, Ancona, Italy
| | - A. Patrizi
- Dermatology Unit, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy
| | - K. Peris
- Institute of Dermatology, Catholic University, Rome, Italy
- Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
| | - A. Costanzo
- Dermatology Unit, Department of Biomedical Sciences, Humanitas University and Humanitas Clinical and Research Center, Rozzano, Italy
| | - G. Malara
- Dermatology Department, Grande Ospedale Metropolitano, Bianchi Melacrino Morelli, Reggio Calabria, Italy
| | - G. Pellacani
- Department of Dermatology, University of Modena and Reggio Emilia, Modena, Italy
| | - M. Romanelli
- Dermatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
| | - P. Amerio
- Department of Medicine and Aging Science, Dermatologic Clinic, G. D’Annunzio University, Chieti, Italy
| | - A. Cristaudo
- Unit of Dermatology, San Gallicano Dermatological Institute-IRCCS, Rome, Italy
| | - M. L. Flori
- Dermatology Section, Department of Clinical Medicine and Immunological Science, University of Siena, Hospital S. Maria Alle Scotte, Siena, Italy
| | - A. Motolese
- Department of Dermatology, IRCCS Santa Maria Nuova, Reggio Emilia, Italy
| | - P. Betto
- Department of Dermatology, ULSS8 Berica, Vicenza, Italy
| | - C. Patruno
- Department of Health Sciences, University Magna Graecia of Catanzaro, Catanzaro, Italy
| | - P. Pigatto
- Department of Biomedical, Surgical and Dental Sciences, Clinical Dermatology, IRCCS Galeazzi Orthopaedic Institute, University of Milan, Milan, Italy
| | - C. Peccianti
- Unit of Dermatology, Ospedale Della Misericordia, Grosseto, Italy
| | - G. Stinco
- Department of Medicine, Institute of Dermatology, University of Udine, Udine, Italy
| | - I. Zalaudek
- Dermatology Clinic, Hospital Maggiore of Trieste, Trieste, Italy
| | - L. Bianchi
- Department of Dermatology, University of Tor Vergata, Rome, Italy
| | - V. Boccaletti
- Section of Dermatology, Department of Clinical and Experimental Medicine, University Hospital, Parma
| | - S. P. Cannavo
- Dermatology, Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy
| | - F. Cusano
- Dermatology Unit, Gaetano Rummo Hospital Benevento, Benevento, Italy
| | - S. Lembo
- Unit of Dermatology, Hospital Santa Maria Incoronata Dell’Olmo, Cava De’ Tirreni, University Hospital San Giovanni di Dio e Ruggi di Salerno, Salerno, Italy
| | - R. Mozzillo
- Dermatology and Venereology, San Gennaro Hospital, Naples, Italy
| | - R. Gallo
- Dermatology Section, Department of Health Science, University of Genoa, Polyclinic Hospital San Martino, Genoa, Italy
| | - C. Potenza
- Dermatology Unit, Department of Medical and Surgical Sciences and Biotechnologies, Daniele Innocenzi, Sapienza University of Rome, Rome, Italy
| | - F. Rongioletti
- Section of Dermatology, Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy
| | - R. Tiberio
- Department of Health Science, University of Eastern Piedmont, Novara, Italy
| | - T. Grieco
- Unit of Dermatology Clinic Umberto I, Sapienza University of Rome, Rome, Italy
| | - G. Micali
- Unit of Dermatology Clinic, University of Catania, Catania, Italy
| | - S. Persechino
- Unit of Dermatology, Sant’Andrea Hospital, NESMOS Department, Sapienza University of Rome, Rome, Italy
| | - M. Pettinato
- Unit of Dermatology, University Hospital, Policlinico Vittorio Emanuele, Catania, Italy
| | - S. Pucci
- Allergology, Hospital of Civitanova Marche, Civitanova Marche, Italy
| | - L. Stingeni
- Dermatology Section, Department of Medicine, University of Perugia, Perugia, Italy
| | - C. Caruso
- Unit of Allergy, Fondazione Policlinico Universitario A. Gemelli, IRCCS Rome, Italy
| | - G. Argenziano
- Unit of Dermatology, University of Campania Luigi Vanvitelli, Naples, Italy
| |
Collapse
|
20
|
Rey F, Gallo R. Benefit of upstream Impella insertion in cardiogenic shock. Cardiovasc Med 2020. [DOI: 10.4414/cvm.2020.02090] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Affiliation(s)
- Florian Rey
- Fellow
- cardiology
- 5000, rue Bélanger
- Montréal
- Québec
- SWITZERLAND
| | | |
Collapse
|
21
|
Damiani G, Calzavara‐Pinton P, Stingeni L, Hansel K, Cusano F, Pigatto PD, Agostinelli D, Albertazzi D, Angelini G, Angerosa F, Arigliano P, Assalve D, Ayala F, Barbagallo T, Belloni‐Fortina A, Berta M, Biale C, Bianchi L, Biasini I, Boccaletti V, Bonamonte D, Borghi A, Bragazzi N, Brambilla L, Bressan M, Brunasso A, Bruni F, Bruni P, Caccavale S, Calogiuri G, Cannavò S, Carugno A, Cataldi I, Chiarelli G, Cirla A, Corazza M, Cossutta M, Cova L, Cristaudo A, Cusano F, Danese P, Dal Canton M, De Pità O, De Salvo P, Donini M, Fantini F, Ferrucci S, Flori M, Fontana E, Foti C, Francalci S, Frasin L, Gallo R, Gasparini G, Gola M, Gravante M, Guarnieri F, Guastaferro D, Ingordo V, Lauriola M, Leghissa P, Lisi P, Lombardi P, Lorenzini M, Malara G, Magrini L, Marone G, Martina E, Mascagni P, Matteini Chiari M, Meligeni L, Melino M, Miccio L, Milanesi N, Molinu A, Monfrecola G, Morelli P, Motolese A, Musumeci M, Naldi L, Napolitano M, Nasca M, Pacifico A, Paganini P, Papini M, Pasolini G, Patruno C, Pellegrino M, Peroni A, Peserico A, Piras V, Pugliese A, Raponi F, Raviolo P, Rebora A, Recchia G, Riva F, Romita P, Rossi M, Ruggieri M, Saggiorato F, Sartorelli P, Schena D, Schettino A, Spanò G, Stinchi C, Tasin L, Tramontana M, Taddei L, Valsecchi R, Russo F, Vascellaro A, Venturini M, Vincenzi C, Virgili A, Zucca M. Italian guidelines for therapy of atopic dermatitis—Adapted from consensus‐based European guidelines for treatment of atopic eczema (atopic dermatitis). Dermatol Ther 2019; 32:e13121. [DOI: 10.1111/dth.13121] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2019] [Revised: 10/04/2019] [Accepted: 10/11/2019] [Indexed: 12/13/2022]
Affiliation(s)
- Giovanni Damiani
- Department of Biomedical, Surgical, and Dental Sciences Unit of DermatologyUniversity of Milan Milan Italy
- IRCCS Istituto Ortopedico Galeazzi Milan Italy
- Young Dermatologists Italian NetworkGISED Bergamo Italy
- Department of DermatologyCase Western Reserve University Cleveland Ohio
| | | | - Luca Stingeni
- Section of Dermatology, Department of MedicineUniversity of Perugia Perugia Italy
| | - Katharina Hansel
- Section of Dermatology, Department of MedicineUniversity of Perugia Perugia Italy
| | | | - Paolo D.M. Pigatto
- Department of Biomedical, Surgical, and Dental Sciences Unit of DermatologyUniversity of Milan Milan Italy
- IRCCS Istituto Ortopedico Galeazzi Milan Italy
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Fargnoli MC, Esposito M, Ferrucci S, Girolomoni G, Offidani A, Patrizi A, Peris K, Costanzo A, Malara G, Pellacani G, Romanelli M, Amerio P, Cristaudo A, Flori ML, Motolese A, Betto P, Patruno C, Pigatto P, Sirna R, Stinco G, Zalaudek I, Bianchi L, Boccaletti V, Cannavò SP, Cusano F, Lembo S, Mozzillo R, Gallo R, Potenza C, Rongioletti F, Tiberio R, Grieco T, Micali G, Persechino S, Pettinato M, Pucci S, Savi E, Stingeni L, Romano A, Argenziano G. Real-life experience on effectiveness and safety of dupilumab in adult patients with moderate-to-severe atopic dermatitis. J DERMATOL TREAT 2019; 32:507-513. [DOI: 10.1080/09546634.2019.1682503] [Citation(s) in RCA: 36] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Affiliation(s)
- M. C. Fargnoli
- Dermatology Unit, Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila, L’Aquila, Italy
| | - M. Esposito
- Dermatology Unit, Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila, L’Aquila, Italy
| | - S. Ferrucci
- Unit of Dermatology, Fondazione IRCCS Ca’ Grande Ospedale Maggiore Policlinico, Milan, Italy
| | - G. Girolomoni
- Section of Dermatology and Venereology, Department of Medicine, University of Verona, Verona, Italy
| | - A. Offidani
- Dermatology Unit, Department of Clinical and Molecular Sciences, Polytechnic Marche University, Ancona, Italy
| | - A. Patrizi
- Dermatology Unit, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy
| | - K. Peris
- Institute of Dermatology, Catholic University, Rome, Italy
- Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
| | - A. Costanzo
- Dermatology Unit, Department of Biomedical Sciences, Humanitas University and Humanitas Clinical and Research Center, Rozzano, Italy
| | - G. Malara
- Dermatology Department, Grande Ospedale Metropolitano, Bianchi Melacrino Morelli, Reggio Calabria, Italy
| | - G. Pellacani
- Department of Dermatology, University of Modena and Reggio Emilia, Modena, Italy
| | - M. Romanelli
- Dermatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
| | - P. Amerio
- Department of Medicine and Aging Science, Dermatologic Clinic, G. D’Annunzio University, Chieti, Italy
| | - A. Cristaudo
- Unit of Dermatology, San Gallicano Dermatological Institute-IRCCS, Rome, Italy
| | - M. L. Flori
- Dermatology Section, Department of Clinical Medicine and Immunological Science, University of Siena, Hospital S. Maria Alle Scotte, Siena, Italy
| | - A. Motolese
- Department of Dermatology, Macchi Hospital, Varese, Italy
| | - P. Betto
- Department of Dermatology, Ospedale San Bortolo, ULSS8 Berica, Vicenza, Italy
| | - C. Patruno
- Department of Health Sciences, University Magna Graecia of Catanzaro, Catanzaro, Italy
| | - P. Pigatto
- Department of Biomedical, Surgical and Dental Sciences, Clinical Dermatology, IRCCS Galeazzi Orthopaedic Institute, University of Milan, Milan, Italy
| | - R. Sirna
- Unit of Dermatology, Ospedale Della Misericordia, Grosseto, Italy
| | - G. Stinco
- Department of Medicine, Institute of Dermatology, University of Udine, Udine, Italy
| | - I. Zalaudek
- Dermatology Clinic, Hospital Maggiore of Trieste, Trieste, Italy
| | - L. Bianchi
- Department of Dermatology, University of Tor Vergata, Rome, Italy
| | - V. Boccaletti
- Section of Dermatology, Department of Clinical and Experimental Medicine, University Hospital, Parma
| | - S. P. Cannavò
- Dermatology, Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy
| | - F. Cusano
- Dermatology Unit, Gaetano Rummo Hospital Benevento, Benevento, Italy
| | - S. Lembo
- Unit of Dermatology, University Hospital San Giovanni di Dio e Ruggi di Salerno, Hospital Santa Maria Incoronata Dell’Olmo, Cava De’ Tirreni, Salerno, Italy
| | - R. Mozzillo
- Dermatology and Venereology, “San Gennaro” Hospital, Naples, Italy
| | - R. Gallo
- Dermatology Section, Department of Health Science, University of Genoa, Polyclinic Hospital San Martino, Genoa, Italy
| | - C. Potenza
- Dermatology Unit, Department of Medical and Surgical Sciences and Biotechnologies, Daniele Innocenzi, Sapienza University of Rome - Polo Pontino, Rome, Italy
| | - F. Rongioletti
- Section of Dermatology, Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy
| | - R. Tiberio
- Department of Health Science, University of Eastern Piedmont, Novara, Italy
| | - T. Grieco
- Dermatology Clinic Umberto I, Sapienza University of Rome, Rome, Italy
| | - G. Micali
- Dermatology Clinic, University of Catania, Catania, Italy
| | - S. Persechino
- Dermatology Unit, Sant’Andrea Hospital, NESMOS Department, Sapienza University of Rome, Rome, Italy
| | - M. Pettinato
- Unit of Dermatology, University Hospital, Policlinico Vittorio Emanuele, Catania, Italy
| | - S. Pucci
- Allergology, Hospital of Civitanova Marche, Civitanova Marche, Italy
| | - E. Savi
- Unit of Dermatology, Hospital Guglielmo da Saliceto, Piacenza, Italy
| | - L. Stingeni
- Dermatology Section, Department of Medicine, University of Perugia, Perugia, Italy
| | - A. Romano
- Allergology Unit, Columbus Presidium, Catholic University, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
| | - G. Argenziano
- Dermatology Unit, University of Campania Luigi Vanvitelli, Naples, Italy
| | | |
Collapse
|
23
|
Cau L, Williams M, Nakatsuji T, Mainzer C, Closs B, Horswill A, Gallo R. 400 Staphylococccus epidermidis can exacerbate atopic dermatitis through the secretion of the cysteine protease EcpA. J Invest Dermatol 2019. [DOI: 10.1016/j.jid.2019.07.402] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
24
|
Horsley V, Glass D, Minnillo R, Gallo R, Cruz P, Ward NL. Diversity is Excellence: Initiatives in the Society for Investigative Dermatology to Broaden Participation. J Invest Dermatol 2019; 139:2217-2219. [PMID: 31381893 DOI: 10.1016/j.jid.2019.07.695] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2019] [Accepted: 07/18/2019] [Indexed: 10/26/2022]
Affiliation(s)
- Valerie Horsley
- Department of Molecular, Cellular and Developmental Biology, Yale University, New Haven, Connecticut; Department of Dermatology, Yale University School of Medicine, New Haven, Connecticut.
| | - Donald Glass
- Department of Dermatology, University of Texas Southwestern Medical Center, Dallas, Texas
| | | | - Richard Gallo
- Department of Dermatology, University of California, San Diego, California
| | - Ponciano Cruz
- Department of Dermatology, University of Texas Southwestern Medical Center, Dallas, Texas
| | - Nicole L Ward
- Departments of Nutrition and Dermatology, Case Western University, Cleveland, Ohio
| |
Collapse
|
25
|
Gallo R, Pettinicchio V, Santoro V, Trinito MO, Minardi V, Contoli B, Masocco M. Health counseling and lifestyles. The Italian Behavioral Risk Factor Surveillance System data. Eur J Public Health 2018. [DOI: 10.1093/eurpub/cky212.100] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- R Gallo
- Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy
| | - V Pettinicchio
- Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy
| | - V Santoro
- Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy
| | - MO Trinito
- Department of Prevention, Local Health Unit “Roma 2”, Rome, Italy
| | - V Minardi
- National Institute of Health, National Center for Disease Prevention and Health Promotion, Rome, Italy
| | - B Contoli
- National Institute of Health, National Center for Disease Prevention and Health Promotion, Rome, Italy
| | - M Masocco
- National Institute of Health, National Center for Disease Prevention and Health Promotion, Rome, Italy
| |
Collapse
|
26
|
Santoro V, Pettinicchio V, Gallo R, Fateh-Moghadam P, Carrozzi G, Campostrini S, Sampaolo L, Minardi V, Contoli B, Masocco M, Battisti L. Passi surveillance and health professionals’ attitude toward healthy habits and citizenship in Italy. Eur J Public Health 2018. [DOI: 10.1093/eurpub/cky214.192] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- V Santoro
- Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy
| | - V Pettinicchio
- Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy
| | - R Gallo
- Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy
| | - P Fateh-Moghadam
- Health Education Service, Provincial Agency for Health Services, Provincia Autonoma di Trento, Italy
| | - G Carrozzi
- Department of Public Health, Local Health Unit, Modena, Italy
| | - S Campostrini
- Department of Economics, Ca’ Foscari University of Venice, Venice, Italy
| | - L Sampaolo
- Department of Economics, Ca’ Foscari University of Venice, Venice, Italy
| | - V Minardi
- National Institute of Health, National Centre for Diseases Prevention and Health Promotion, Rome, Italy
| | - B Contoli
- National Institute of Health, National Centre for Diseases Prevention and Health Promotion, Rome, Italy
| | - M Masocco
- National Institute of Health, National Centre for Diseases Prevention and Health Promotion, Rome, Italy
| | - L Battisti
- Health Education Service, Provincial Agency for Health Services, Provincia Autonoma di Trento, Italy
| |
Collapse
|
27
|
Vidovic Š, Vinko M, Ivankovic D, Massonnaud C, Cabral de Pinho M, Raguzzoni G, Gallo R, Guicciardi S, Mateo A, Cerasuolo D, Zaletel-Kragelj L. An assessment of public health residency learning climate in Europe - developing a tool. Eur J Public Health 2018. [DOI: 10.1093/eurpub/cky212.541] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- Š Vidovic
- National Institute of Public Health, Ljubljana, Slovenia
| | - M Vinko
- National Institute of Public Health, Ljubljana, Slovenia
| | - D Ivankovic
- Croatian Institute of Public Health, Zagreb, Croatia
| | | | - M Cabral de Pinho
- Unidade de Saúde Pública António Luz - ACES Amadora, Amadora, Portugal
| | - G Raguzzoni
- Institute of Hygiene and Public Health, Bologna, Italy
| | - R Gallo
- University of Rome Tor Vergata, Department of Biomedicine and Prevention, Rome, Italy
| | - S Guicciardi
- Institute of Hygiene and Public Health, Bologna, Italy
| | - A Mateo
- Public Health England, Liverpool, UK
| | | | - L Zaletel-Kragelj
- Faculty of Medicine, Department of Public Health, University of Ljubljana, Ljubljana, Slovenia
| |
Collapse
|
28
|
Gallo R, Maiarota F, Dodaro G, Zdravkovic I, Sorbello M. Editorial comment to the case report awake extubation: Anesthesia and the perfect flight. Trends in Anaesthesia and Critical Care 2018. [DOI: 10.1016/j.tacc.2018.04.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
29
|
Civelli EM, Gallino G, Mariani L, Cozzi G, Biganzoli E, Salvetti M, Gallo R, Belli F, Bonfanti G, Bertario L, Andreola S, Leo E. Double-Contrast Barium Enema and Computerised Tomography in the Pre-Operative Evaluation of Rectal Carcinoma: Are they Still Useful Diagnostic Procedures? Tumori 2018; 86:389-92. [PMID: 11130567 DOI: 10.1177/030089160008600504] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Purpose In modern management of rectal carcinoma, the preoperative evaluation of disease parameters is important for selection of therapeutic options. Such parameters are currently defined through endorectal ultrasonography or endoscopic ultrasonography. A retrospective analysis of the parameters obtained with double-contrast barium enema (DCBE) and endorectal balloon computed tomography (CT) was conducted to verify the diagnostic reliability of the radiological techniques and to establish whether there is still an indication for their use. Methods 53 consecutive patients with adenocarcinoma of the distal half of the rectal ampulla underwent double contrast barium enema examination and CT of the pelvis with endorectal balloon. On the basis of the DCBE and CT assessment we evaluated: 1) the distance between the cranial extremity of the anal canal and the distal margin of the neoplasm; 2) the radial diffusion of the tumor; 3) the metastatic involvement of the perirectal and inferior mesenteric lymph nodes. Results 1) CT and DBCE measurements of the distal margin tended to coincide, but both tended to overestimate the measurement when compared to the pathologic examination; 2) in the identification of neoplastic infiltration of perirectal fat (T3) CT had 100% sensitivity, 78.7% specificity and 86.8% accuracy; 3) the CT sensitivity for detecting lymph node metastasis was 52.6%, specificity 85.3% and accuracy 73.6%. Conclusions The diagnostic information provided by the radiological examinations is comparable to that of clinical and instrumental methods currently employed for staging of rectal carcinoma, although the latter are preferred because they are more readily accessible and less costly. DCBE and CT can therefore be usefully employed for staging of cancer of the rectum in those cases in which there are limitations of the current standard methods.
Collapse
Affiliation(s)
- E M Civelli
- Department of Radiology, Istituto Nazionale perlo Studio e la Cura dei Tumori, Milan, Italy
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Spagnoli V, Picard F, Tadros VX, Cournoyer D, Doucet S, Tanguay JF, Gosselin G, de Guise P, Gallo R. Simplifying the assessment of coronary artery stenosis by enhancing instantaneous wave free ratio. Cardiovasc Diagn Ther 2018; 8:156-163. [PMID: 29850406 DOI: 10.21037/cdt.2017.12.04] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023]
Abstract
Background Instantaneous wave free ratio (iFR) does not require adenosine, but has a relatively wide intermediate range where functional assessment remains inconclusive. In this pilot study, we sought to enhance iFR through with the use of intracoronary (IC) saline (iFRs) and contrast media (iFRc) and determine whether these techniques correlated well with fractional flow reserve (FFR). Methods Patients with coronary artery stenosis (CAS) associated with an iFR in the intermediate zone (≥0.86 and ≤0.93) were prospectively assessed with resting distal coronary pressure/aorta pressure (Pd/Pa), iFR, iFRs, iFRc and FFR. Results A total of 40 coronary lesions were studied (40 patients). Pearson correlation coefficients for FFR and iFR, FFR and iFRs, FFR and iFRc were respectively: 0.57 (P=0.0002), 0.80 (P<0.0001) and 0.77 (P<0.0001). Receiver-operating characteristic (ROC) curve analysis showed similar area under the curve (AUC) of iFRs and iFR [0.90 (95% CI: 0.76-1) vs. 0.89 (95% CI: 0.79-0.99), P=0.89]. Youden's index established cut-off values of ≤0.90 for iFR (sensitivity =91%, specificity =74%) and ≤0.78 for iFRs (sensitivity =73%, specificity =100%). In contrast, the AUC of iFRc was superior to the AUC of iFR [0.99 (95% CI: 0.98-1), P=0.049]. iFRc showed excellent accuracy and established cut-off values of ≤0.81 in predicting an FFR value of ≤0.80 (sensitivity =100%, specificity =93%). Conclusions When iFR is in the intermediate zone, functional assessment of CAS by iFR is enhanced with the use of contrast media but not saline. This pilot study could be hypothesis generating for further study to enhance iFR specificity and sensibility.
Collapse
Affiliation(s)
- Vincent Spagnoli
- Department of Cardiology, Montréal Heart Institute, Université de Montréal, Montréal, Canada
| | - Fabien Picard
- Department of Cardiology, Montréal Heart Institute, Université de Montréal, Montréal, Canada
| | - Victor-Xavier Tadros
- Department of Cardiology, Montréal Heart Institute, Université de Montréal, Montréal, Canada
| | | | - Serge Doucet
- Department of Cardiology, Montréal Heart Institute, Université de Montréal, Montréal, Canada
| | - Jean François Tanguay
- Department of Cardiology, Montréal Heart Institute, Université de Montréal, Montréal, Canada
| | - Gilbert Gosselin
- Department of Cardiology, Montréal Heart Institute, Université de Montréal, Montréal, Canada
| | - Pierre de Guise
- Department of Cardiology, Montréal Heart Institute, Université de Montréal, Montréal, Canada
| | - Richard Gallo
- Department of Cardiology, Montréal Heart Institute, Université de Montréal, Montréal, Canada
| |
Collapse
|
31
|
Uter W, Amario-Hita J, Balato A, Ballmer-Weber B, Bauer A, Belloni Fortina A, Bircher A, Chowdhury M, Cooper S, Czarnecka-Operacz M, Dugonik A, Gallo R, Giménez-Arnau A, Johansen J, John S, Kieć-Świerczyńska M, Kmecl T, Kręcisz B, Larese Filon F, Mahler V, Pesonen M, Rustemeyer T, Sadowska-Przytocka A, Sánchez-Pérez J, Schliemann S, Schuttelaar M, Simon D, Spiewak R, Valiukevičienė S, Weisshaar E, White I, Wilkinson S. European Surveillance System on Contact Allergies (ESSCA): results with the European baseline series, 2013/14. J Eur Acad Dermatol Venereol 2017. [DOI: 10.1111/jdv.14423] [Citation(s) in RCA: 63] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Affiliation(s)
- W. Uter
- Department of Medical Informatics; Biometry and Epidemiology; Friedrich-Alexander-University Erlangen/Nürnberg; Erlangen Germany
| | - J.C. Amario-Hita
- Department of Dermatology; University Hospital of Puerto Real; Cádiz Spain
| | - A. Balato
- Department of Advanced Biomedical Sciences; University of Naples Federico II; Napoli Italy
| | - B. Ballmer-Weber
- Department of Dermatology; University Hospital Zürich; Zürich Switzerland
- Centre for Dermatology and Allergology; Kantonsspital Luzern; Luzern Switzerland
| | - A. Bauer
- Department of Dermatology; University Hospital Carl Gustav Carus; Technical University of Dresden; Dresden Germany
| | - A. Belloni Fortina
- Pediatric Dermatology Unit; Department of Medicine DIMED; University of Padova; Padova Italy
| | - A. Bircher
- Allergology Unit; Department of Dermatology; University Hospital Basel; Basel Switzerland
| | - M.M.U. Chowdhury
- The Welsh Institute of Dermatology; University Hospital of Wales; Cardiff UK
| | | | | | - A. Dugonik
- Department of Dermatology; University Medical Center Maribor; Maribor Slovenia
| | - R. Gallo
- Clinica Dermatologica; IRCCS - AOU San Martino - IST and Department of Health Sciences; University of Genoa; Genoa Italy
| | - A. Giménez-Arnau
- Department of Dermatology; Hospital del Mar; Universitat Autónoma; Barcelona Spain
| | - J.D. Johansen
- National Allergy Centre/Department of Dermatology; Gentofte Hospital; University of Copenhagen; Hellerup Denmark
| | - S.M. John
- Department of Dermatology; Institute for Interdisciplinary Dermatologic Prevention and Rehabilitation (iDerm); University of Osnabrück; Lower Saxony Institute for Occupational Dermatology (NIB); Osnabrück Germany
| | - M. Kieć-Świerczyńska
- Department of Dermatology; Nofer Institute of Occupational Medicine; Łodz Poland
| | - T. Kmecl
- Department of Dermatology; General Hospital Celje; Celje Slovenia
| | - B. Kręcisz
- Department of Dermatology; Nofer Institute of Occupational Medicine; Łodz Poland
- Faculty of Medicine and Health Science; Institute of Medical Science; Jan Kochanowski University; Kielce Poland
| | - F. Larese Filon
- Department of Public Health, Occupational Medicine; University of Trieste; Trieste Italy
| | - V. Mahler
- Department of Dermatology; University Hospital Erlangen; Friedrich-Alexander-University Erlangen-Nürnberg; Erlangen Germany
| | - M. Pesonen
- Occupational Medicine; Finnish Institute of Occupational Health (FIOH); Helsinki Finland
| | - T. Rustemeyer
- Department of Dermatology; Free University of Amsterdam; Amsterdam The Netherlands
| | | | - J. Sánchez-Pérez
- Department of Dermatology; Hospital Universitario la Princesa; Madrid Spain
| | - S. Schliemann
- Department of Dermatology and Allergology; University Hospital Jena; Jena Germany
| | - M.L. Schuttelaar
- Department of Dermatology; University Medical Centre Groningen; University of Groningen; Groningen The Netherlands
| | - D. Simon
- Department of Dermatology; Inselspital; Bern University Hospital; University of Bern; Bern Switzerland
| | - R. Spiewak
- Department of Experimental Dermatology and Cosmetology; Faculty of Pharmacy; Jagiellonian University Medical College; Krakow Poland
| | - S. Valiukevičienė
- Department of Skin and Venereal Diseases; Lithuanian University of Health Sciences; Kaunas Lithuania
| | - E. Weisshaar
- Department of Clinical Social Medicine; University Hospital Heidelberg; Heidelberg Germany
| | - I.R. White
- St. John's Institute of Dermatology; Guy's Hospital; London UK
| | - S.M. Wilkinson
- Dermatology; Leeds Teaching Hospitals NHS Trust; Leeds UK
| |
Collapse
|
32
|
Belle C, Béraud C, Faure D, Gallo R, Hoornaert P, Martin JM, Rey C. Mécanisme des réactions polyphasiques : cinétique de formation de carbonate de calcium colloïdal en milieu apolaire. ACTA ACUST UNITED AC 2017. [DOI: 10.1051/jcp/1990870093] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
33
|
Spagnoli V, Picard F, Tadros V, Cournoyer D, Doucet S, Tanguay J, Gosselin G, Deguise P, Gallo R. Simplifying the Assessment of Coronary Artery Stenosis by Enhancing Instantaneous Wave Free Ratio. Archives of Cardiovascular Diseases Supplements 2017. [DOI: 10.1016/s1878-6480(17)30382-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
34
|
Gupta S, Winglee K, Gallo R, Bishai WR. Bacterial subversion of cAMP signalling inhibits cathelicidin expression, which is required for innate resistance to Mycobacterium tuberculosis. J Pathol 2017; 242:52-61. [PMID: 28097645 DOI: 10.1002/path.4878] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2016] [Revised: 12/14/2016] [Accepted: 01/03/2017] [Indexed: 01/03/2023]
Abstract
Antimicrobial peptides such as cathelicidins are important components of innate immune defence against inhaled microorganisms, and have shown antimicrobial activity against Mycobacterium tuberculosis in in vitro models. Despite this, little is known about the regulation and expression of cathelicidin during tuberculosis in vivo. We sought to determine whether the cathelicidin-related antimicrobial peptide gene (Cramp), the murine functional homologue of the human cathelicidin gene (CAMP or LL-37), is required for regulation of protective immunity during M. tuberculosis infection in vivo. We used Cramp-/- mice in a validated model of pulmonary tuberculosis, and conducted cell-based assays with macrophages from these mice. We evaluated the in vivo susceptibility of Cramp-/- mice to infection, and also dissected various pro-inflammatory immune responses against M. tuberculosis. We observed increased susceptibility of Cramp-/- mice to M. tuberculosis as compared with wild-type mice. Macrophages from Cramp-/- mice were unable to control M. tuberculosis growth in an in vitro infection model, were deficient in intracellular calcium influx, and were defective in stimulating T cells. Additionally, CD4+ and CD8+ T cells from Cramp-/- mice produced less interferon-β upon stimulation. Furthermore, bacterial-derived cAMP modulated cathelicidin expression in macrophages. Our results demonstrate that cathelicidin is required for innate resistance to M. tuberculosis in a relevant animal model and is a key mediator in regulation of the levels of pro-inflammatory cytokines by calcium and cyclic nucleotides. Copyright © 2017 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
Collapse
Affiliation(s)
- Shashank Gupta
- Center for Tuberculosis Research, Department of Medicine, JHU, Baltimore, MD, USA.,Howard Hughes Medical Institute, Chevy Chase, MD, USA
| | - Kathryn Winglee
- Center for Tuberculosis Research, Department of Medicine, JHU, Baltimore, MD, USA
| | - Richard Gallo
- University of California at San Diego, La Jolla, CA, USA
| | - William R Bishai
- Center for Tuberculosis Research, Department of Medicine, JHU, Baltimore, MD, USA.,Howard Hughes Medical Institute, Chevy Chase, MD, USA
| |
Collapse
|
35
|
Tan J, Almeida LMC, Bewley A, Cribier B, Dlova NC, Gallo R, Kautz G, Mannis M, Oon HH, Rajagopalan M, Steinhoff M, Thiboutot D, Troielli P, Webster G, Wu Y, van Zuuren EJ, Schaller M. Updating the diagnosis, classification and assessment of rosacea: recommendations from the global ROSacea COnsensus (ROSCO) panel. Br J Dermatol 2017; 176:431-438. [PMID: 27718519 DOI: 10.1111/bjd.15122] [Citation(s) in RCA: 124] [Impact Index Per Article: 17.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/05/2016] [Indexed: 12/16/2022]
Abstract
BACKGROUND Rosacea is currently diagnosed by consensus-defined primary and secondary features and managed by subtype. However, individual features (phenotypes) can span multiple subtypes, which has implications for clinical practice and research. Adopting a phenotype-led approach may facilitate patient-centred management. OBJECTIVES To advance clinical practice by obtaining international consensus to establish a phenotype-led rosacea diagnosis and classification scheme with global representation. METHODS Seventeen dermatologists and three ophthalmologists used a modified Delphi approach to reach consensus on statements pertaining to critical aspects of rosacea diagnosis, classification and severity evaluation. All voting was electronic and blinded. RESULTS Consensus was achieved for transitioning to a phenotype-based approach to rosacea diagnosis and classification. The following two features were independently considered diagnostic for rosacea: (i) persistent, centrofacial erythema associated with periodic intensification; and (ii) phymatous changes. Flushing, telangiectasia, inflammatory lesions and ocular manifestations were not considered to be individually diagnostic. The panel reached agreement on dimensions for phenotype severity measures and established the importance of assessing the patient burden of rosacea. CONCLUSIONS The panel recommended an approach for diagnosis and classification of rosacea based on disease phenotype.
Collapse
Affiliation(s)
- J Tan
- Department of Medicine, University of Western Ontario, Windsor, ON, Canada
| | - L M C Almeida
- Faculdade de Ciências Médicas de Minas Gerais, Belo Horizonte, Brazil
| | - A Bewley
- Whipps Cross University Hospital, London, U.K.,Royal London Hospital, London, U.K
| | - B Cribier
- Department of Dermatology, Hopitaux Universitaires de Strasbourg, Strasbourg, Alsace, France
| | - N C Dlova
- Department of Dermatology, University of KwaZulu-Natal College of Health Sciences, Durban, South Africa
| | - R Gallo
- Department of Dermatology, University of California San Diego, La Jolla, CA, U.S.A
| | - G Kautz
- Haut- und Laserklinik, Konz, Germany
| | - M Mannis
- Department of Ophthalmology and Vision Science, University of California Davis, Davis, CA, U.S.A
| | - H H Oon
- National Skin Centre, Singapore, Singapore
| | - M Rajagopalan
- Department of Dermatology, Apollo Hospitals Enterprise, Chennai, Tamil Nadu, India
| | - M Steinhoff
- Department of Dermatology and UCD Charles Institute for Translational Dermatology, University College Dublin, Dublin, Ireland
| | - D Thiboutot
- Department of Dermatology, Pennsylvania State University College of Medicine, Hershey, PA, U.S.A
| | - P Troielli
- Faculty of Dermatology, School of Medicine, Universidad de Buenos Aires, Buenos Aires, Argentina
| | - G Webster
- Department of Dermatology and Cutaneous Biology, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA, U.S.A
| | - Y Wu
- Department of Dermatology, Peking University First Hospital, Beijing, China
| | - E J van Zuuren
- Department of Dermatology, Leiden University Medical Centre, Leiden, the Netherlands
| | - M Schaller
- Department of Dermatology, Universitatsklinikum Tubingen, Tubingen, Baden-Württemberg, Germany
| |
Collapse
|
36
|
Stähli BE, Tardif JC, Carrier M, Gallo R, Emery RW, Robb S, Cournoyer D, Blondeau L, Johnson D, Mann J, Lespérance J, Guertin MC, L'Allier PL. Effects of P-Selectin Antagonist Inclacumab in Patients Undergoing Coronary Artery Bypass Graft Surgery: SELECT-CABG Trial. J Am Coll Cardiol 2016; 67:344-6. [PMID: 26796402 DOI: 10.1016/j.jacc.2015.10.071] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/18/2015] [Revised: 10/08/2015] [Accepted: 10/20/2015] [Indexed: 10/22/2022]
|
37
|
Chun K, Afshar M, Audish D, Kabigting F, Paik A, Gallo R, Hata T. Hepatitis C may enhance key amplifiers of psoriasis. J Eur Acad Dermatol Venereol 2016; 31:672-678. [PMID: 27184185 DOI: 10.1111/jdv.13578] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2015] [Accepted: 11/27/2015] [Indexed: 12/13/2022]
Abstract
BACKGROUND Multiple studies have noted an association between hepatitis C and psoriasis, but it is not known whether psoriasis is a result of treatment modalities for hepatitis C or a result of hepatitis C alone. OBJECTIVE To examine the relationship between psoriasis and hepatitis C by measuring the expression of cathelicidin, TLR9 and IFNγ in psoriatic lesional and non-lesional skin in HCV-positive and negative psoriatic patients. METHODS Two 2 mm punch biopsies of lesional and non-lesional skin in 10 patients who were HCV-negative psoriatics and seven HCV-positive psoriatics were used to measure cathelicidin, TLR9 and IFNγ mRNA expression by quantitative reverse-transcriptase polymerase chain reaction (qRT-PCR). RESULTS The mRNA levels of cathelicidin, TLR9 and IFNγ were significantly higher in both non-lesional and lesional skin of HCV-positive patients with psoriasis as compared to HCV-negative psoriatic patients. Additionally, the IFNγ level in lesional skin of HCV-positive psoriatic patients was higher than the IFNγ level seen in non-lesional skin of those same patients. CONCLUSION These findings suggest that HCV infection upregulates these inflammatory cytokines, possibly increasing susceptibility to developing psoriasis.
Collapse
Affiliation(s)
- K Chun
- Department of Dermatology, University of California, San Diego, CA, USA
| | - M Afshar
- Department of Dermatology, University of California, San Diego, CA, USA
| | - D Audish
- Department of Dermatology, University of California, San Diego, CA, USA
| | - F Kabigting
- Department of Dermatology, University of California, San Diego, CA, USA
| | - A Paik
- Department of Dermatology, University of California, San Diego, CA, USA
| | - R Gallo
- Department of Dermatology, University of California, San Diego, CA, USA
| | - T Hata
- Department of Dermatology, University of California, San Diego, CA, USA
| |
Collapse
|
38
|
Peled A, Sarig O, Samuelov L, Bertolini M, Ziv L, Weissglas-Volkov D, Eskin-Schwartz M, Adase C, Malchin N, Bochner R, Fainberg G, Sugawara K, Baniel A, Tsuruta D, Luxemburg C, Adir N, Goldberg I, Gallo R, Shomron N, Paus R, Sprecher E. 414 A new form of ectodermal dysplasia caused by mutations in TSPEAR. J Invest Dermatol 2016. [DOI: 10.1016/j.jid.2016.02.448] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
39
|
Bochner R, Samuelov L, Sarig O, Li Q, Koetsier J, Adase C, Isakov O, Malchin N, Vodo D, Shayevitch R, Yu B, Fainberg G, Harmon R, Najor N, Godsel L, Warshauer E, Gat A, Goldberg I, Shomron N, Ast G, McLean W, Gallo R, Uitto J, Green K, Sprecher E. 372 CAPN12 function revealed through the study of an atypical case of autosomal recessive congenital ichthyosis. J Invest Dermatol 2016. [DOI: 10.1016/j.jid.2016.02.405] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
40
|
Spagnoli V, de Hemptinne Q, Gallo R. 'Ping pong' thrombectomy. BMJ Case Rep 2016; 2016:10.1136/bcr-2016-214354. [PMID: 27095808 DOI: 10.1136/bcr-2016-214354] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
Affiliation(s)
- Vincent Spagnoli
- Department of Interventional Cardiology, Montreal Heart Institute, Montreal, Quebec, Canada
| | - Quentin de Hemptinne
- Department of Interventional Cardiology, Montreal Heart Institute, Montreal, Quebec, Canada
| | - Richard Gallo
- Department of Interventional Cardiology, Montreal Heart Institute, Montreal, Quebec, Canada
| |
Collapse
|
41
|
Del Rosso JQ, Webster GF, Rosen T, Thiboutot D, Leyden JJ, Gallo R, Walker C, Zhanel G, Eichenfield L. Status Report from the Scientific Panel on Antibiotic Use in Dermatology of the American Acne and Rosacea Society: Part 1: Antibiotic Prescribing Patterns, Sources of Antibiotic Exposure, Antibiotic Consumption and Emergence of Antibiotic Resistance, Impact of Alterations in Antibiotic Prescribing, and Clinical Sequelae of Antibiotic Use. J Clin Aesthet Dermatol 2016; 9:18-24. [PMID: 27462384 PMCID: PMC4898580] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
Oral and topical antibiotics are commonly prescribed in dermatologie practice, often for noninfectious disorders, such as acne vulgaris and rosacea. Concerns related to antibiotic exposure from both medical and nonmedical sources require that clinicians consider in each case why and how antibiotics are being used and to make appropriate adjustments to limit antibiotic exposure whenever possible. This first article of a three-part series discusses prescribing patterns in dermatology, provides an overview of sources of antibiotic exposure, reviews the relative correlations between the magnitude of antibiotic consumption and emergence of antibiotic resistance patterns, evaluates the impact of alterations in antibiotic prescribing, and discusses the potential relevance and clinical sequelae of antibiotic use, with emphasis on how antibiotics are used in dermatology.
Collapse
Affiliation(s)
| | - Guy F. Webster
- Department of Dermatology, Jefferson Medical College, Philadelphia, Pennsylvania
| | - Ted Rosen
- Department of Dermatology, Baylor College of Medicine, Houston, Texas
| | - Diane Thiboutot
- Department of Dermatology, Penn State University, Hershey, Pennsylvania
| | - James J. Leyden
- Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania
| | - Richard Gallo
- Department of Dermatology, University of California San Diego, San Diego, California
| | - Clay Walker
- University of Florida Dental School, Gainesville, Florida
| | - George Zhanel
- Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, Canada
| | - Lawrence Eichenfield
- Department of Dermatology (Pediatrics), University of California San Diego, San Diego, California
| |
Collapse
|
42
|
Grisotto S, Mazzarella E, Borroni M, Gallo R, Greco F, Pignoli E, Marchianò A. Retrospective dose evaluation in adults undergoing recurring CT examinations: Last five years experience in our institution. Phys Med 2016. [DOI: 10.1016/j.ejmp.2016.01.272] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
43
|
Azzalini L, Tosin K, Chabot-Blanchet M, Avram R, Ly HQ, Gaudet B, Gallo R, Doucet S, Tanguay JF, Ibrahim R, Grégoire JC, Crépeau J, Bonan R, de Guise P, Nosair M, Dorval JF, Gosselin G, L'Allier PL, Guertin MC, Asgar AW, Jolicœur EM. The Benefits Conferred by Radial Access for Cardiac Catheterization Are Offset by a Paradoxical Increase in the Rate of Vascular Access Site Complications With Femoral Access: The Campeau Radial Paradox. JACC Cardiovasc Interv 2015; 8:1854-64. [PMID: 26604063 DOI: 10.1016/j.jcin.2015.07.029] [Citation(s) in RCA: 75] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/21/2015] [Accepted: 07/30/2015] [Indexed: 11/29/2022]
Abstract
OBJECTIVES The purpose of this study was to assess whether the benefits conferred by radial access (RA) at an individual level are offset by a proportionally greater incidence of vascular access site complications (VASC) at a population level when femoral access (FA) is performed. BACKGROUND The recent widespread adoption of RA for cardiac catheterization has been associated with increased rates of VASCs when FA is attempted. METHODS Logistic regression was used to calculate the adjusted VASC rate in a contemporary cohort of consecutive patients (2006 to 2008) where both RA and FA were used, and compared it with the adjusted VASC rate observed in a historical control cohort (1996 to 1998) where only FA was used. We calculated the adjusted attributable risk to estimate the proportion of VASC attributable to the introduction of RA in FA patients of the contemporary cohort. RESULTS A total of 17,059 patients were included. At a population level, the VASC rate was higher in the overall contemporary cohort compared with the historical cohort (adjusted rates: 2.91% vs. 1.98%; odds ratio [OR]: 1.48, 95% confidence interval [CI]: 1.17 to 1.89; p = 0.001). In the contemporary cohort, RA patients experienced fewer VASC than FA patients (adjusted rates: 1.44% vs. 4.19%; OR: 0.33, 95% CI: 0.23 to 0.48; p < 0.001). We observed a higher VASC rate in FA patients in the contemporary cohort compared with the historical cohort (adjusted rates: 4.19% vs. 1.98%; OR: 2.16, 95% CI: 1.67 to 2.81; p < 0.001). This finding was consistent for both diagnostic and therapeutic catheterizations separately. The proportion of VASCs attributable to RA in the contemporary FA patients was estimated at 52.7%. CONCLUSIONS In a contemporary population where both RA and FA were used, the safety benefit associated with RA is offset by a paradoxical increase in VASCs among FA patients. The existence of this radial paradox should be taken into consideration, especially among trainees and default radial operators.
Collapse
Affiliation(s)
- Lorenzo Azzalini
- Montreal Heart Institute, Université de Montréal, Montréal, Québec, Canada
| | - Kunle Tosin
- Montreal Heart Institute, Université de Montréal, Montréal, Québec, Canada
| | | | - Robert Avram
- Montreal Heart Institute, Université de Montréal, Montréal, Québec, Canada
| | - Hung Q Ly
- Montreal Heart Institute, Université de Montréal, Montréal, Québec, Canada
| | - Benoit Gaudet
- Montreal Heart Institute, Université de Montréal, Montréal, Québec, Canada
| | - Richard Gallo
- Montreal Heart Institute, Université de Montréal, Montréal, Québec, Canada
| | - Serge Doucet
- Montreal Heart Institute, Université de Montréal, Montréal, Québec, Canada
| | | | - Réda Ibrahim
- Montreal Heart Institute, Université de Montréal, Montréal, Québec, Canada
| | - Jean C Grégoire
- Montreal Heart Institute, Université de Montréal, Montréal, Québec, Canada
| | - Jacques Crépeau
- Montreal Heart Institute, Université de Montréal, Montréal, Québec, Canada
| | - Raoul Bonan
- Montreal Heart Institute, Université de Montréal, Montréal, Québec, Canada
| | - Pierre de Guise
- Montreal Heart Institute, Université de Montréal, Montréal, Québec, Canada
| | - Mohamed Nosair
- Montreal Heart Institute, Université de Montréal, Montréal, Québec, Canada
| | | | - Gilbert Gosselin
- Montreal Heart Institute, Université de Montréal, Montréal, Québec, Canada
| | | | | | - Anita W Asgar
- Montreal Heart Institute, Université de Montréal, Montréal, Québec, Canada
| | - E Marc Jolicœur
- Montreal Heart Institute, Université de Montréal, Montréal, Québec, Canada.
| |
Collapse
|
44
|
de Hemptinne Q, L'Allier P, Jolicoeur M, Asgar A, Bonan R, Crépeau J, de Guise P, Dorval J, Doucet S, Gallo R, Gosselin G, Grégoire J, Ibrahim R, Ly H, Nosair M, Tanguay J. REAL-WORLD CLINICAL OUTCOMES ACCORDING TO DUAL ANTI-PLATELET THERAPY REGIMEN AMONG PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION: SINGLE CENTER EXPERIENCE IN CANADA. Can J Cardiol 2015. [DOI: 10.1016/j.cjca.2015.07.064] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
|
45
|
Liu J, Gallo R, Duffy C, Brutkiewicz R. The inhibition of CD1d-mediated antigen presentation upon an HSV-1 infection is VP22-dependent (VIR1P.1134). The Journal of Immunology 2015. [DOI: 10.4049/jimmunol.194.supp.74.11] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
Abstract
CD1d-restricted T (NKT) cells are important for controlling a herpes simplex virus (HSV) infection. One of the mechanisms of immune evasion by HSV is to down-regulate CD1d-mediated activation of NKT cells. VP22 is an HSV-1-encoded protein responsible for reorganizing the host cell’s cytoskeletal network and viral spreading. We have shown that modification of the cytoskeleton can alter CD1d-mediated antigen presentation. In this study, we found an HSV-1 lacking VP22 (ΔUL49) was impaired in its ability to inhibit CD1d-mediated antigen presentation compared to wild-type (WT) virus; this was reversed by a repair virus (UL49R) in CD1d-expressing cells. Of importance, the effects of VP22 were shown to be exerted on the T322/S323 dyad, critical residues for the virus to reduced antigen presentation. We further demonstrated that CD1d recycling was inhibited by infection with WT and UL49R, but not ΔUL49 virus. Rather than inhibiting antigen presentation by CD1d, ectopic expression of VP22 in CD1d-expressing cells complemented the VP22-deficient virus in inhibiting antigen presentation. Therefore, VP22 is required (but not sufficient) for the inhibition of CD1d-mediated antigen presentation by an HSV-1 infection.
Collapse
Affiliation(s)
- Jianyun Liu
- 1Indiana University, School of Medicine, Indianapolis, IN
| | - Richard Gallo
- 1Indiana University, School of Medicine, Indianapolis, IN
| | - Carol Duffy
- 2Biological Sciences, University of Alabama, Tuscaloosa, AL
| | | |
Collapse
|
46
|
Zhang H, Goodman SG, Yan RT, Steg PG, Kornder JM, Gyenes GT, Grondin FR, Brieger D, DeYoung JP, Gallo R, Yan AT. In-hospital management and outcomes of acute coronary syndromes in relation to prior history of heart failure. Eur Heart J Acute Cardiovasc Care 2015; 5:214-22. [PMID: 25766512 DOI: 10.1177/2048872615574109] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/05/2014] [Accepted: 02/01/2015] [Indexed: 12/18/2022]
Abstract
INTRODUCTION The prognostic significance of prior heart failure in acute coronary syndromes has not been well studied. Accordingly, we evaluated the baseline characteristics, management patterns and clinical outcomes in patients with acute coronary syndromes who had prior heart failure. METHODS AND RESULTS The study population consisted of acute coronary syndrome patients in the Global Registry of Acute Coronary Events, expanded Global Registry of Acute Coronary Events and Canadian Registry of Acute Coronary Events between 1999 and 2008. Of the 13,937 eligible patients (mean age 66±13 years, 33% female and 28.3% with ST-elevation myocardial infarction), 1498 (10.7%) patients had a history of heart failure. Those with prior heart failure tended to be older, female and had lower systolic blood pressure, higher Killip class and creatinine on presentation. Prior heart failure was also associated with significantly worse left ventricular systolic function and lower rates of cardiac catheterization and coronary revascularization. The group with previous heart failure had significantly higher rates of acute decompensated heart failure, cardiogenic shock, myocardial (re)infarction and mortality in hospital. In multivariable analysis, prior heart failure remained an independent predictor of in-hospital mortality (odds ratio 1.48, 95% confidence interval 1.08-2.03, p=0.015). CONCLUSIONS Prior heart failure was associated with high risk features on presentation and adverse outcomes including higher adjusted in-hospital mortality in acute coronary syndrome patients. However, acute coronary syndrome patients with prior heart failure were less likely to receive evidence-based therapies, suggesting potential opportunities to target more intensive treatment to improve their outcome.
Collapse
Affiliation(s)
- Hanfei Zhang
- Terrence Donnelly Heart Centre, St. Michael's Hospital, Canada University of Toronto, Canada
| | - Shaun G Goodman
- Terrence Donnelly Heart Centre, St. Michael's Hospital, Canada University of Toronto, Canada Canadian Heart Research Centre, Canada
| | | | - Ph Gabriel Steg
- DHU FIRE, Université Paris-Diderot, AP-HP, Hôpital Bichat, France
| | | | - Gabor T Gyenes
- Mazankowski Alberta Heart Institute, University of Alberta, Canada
| | | | | | - J Paul DeYoung
- Cornwall Community Hospital, Cornwall and University of Ottawa, Canada
| | | | - Andrew T Yan
- Terrence Donnelly Heart Centre, St. Michael's Hospital, Canada University of Toronto, Canada
| | | |
Collapse
|
47
|
Scalone L, Cortesi P, Mantovani L, Belisari A, Ayala F, Fortina A, Bonamonte D, Borroni G, Cannavò S, Guarneri F, Cristaudo A, De Pità O, Gallo R, Girolomoni G, Gola M, Lisi P, Pigatto P, Satta R, Giannetti A. Clinical epidemiology of hand eczema in patients accessing dermatological reference centres: results from Italy. Br J Dermatol 2014; 172:187-95. [DOI: 10.1111/bjd.13220] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 06/18/2014] [Indexed: 11/27/2022]
Affiliation(s)
- L. Scalone
- Research Centre on Public Health (CESP); University of Milan-Bicocca; Villa Serena Via Pergolesi 33 I-20052 Monza Italy
- CHARTA Foundation; Milan Italy
| | - P.A. Cortesi
- Research Centre on Public Health (CESP); University of Milan-Bicocca; Villa Serena Via Pergolesi 33 I-20052 Monza Italy
- CHARTA Foundation; Milan Italy
| | - L.G. Mantovani
- CHARTA Foundation; Milan Italy
- Faculty of Pharmacy; University of Naples Federico II; Naples Italy
| | | | - F. Ayala
- Department of Dermatology; University of Naples Federico II; Naples Italy
| | - A.B. Fortina
- Pediatric Dermatology Unit; Department of Medicine; University of Padova; Padova Italy
| | - D. Bonamonte
- Department of Biomedical Science and Human Oncology; Unit of Dermatology; University of Bari ‘Aldo Moro’; Bari Italy
| | - G. Borroni
- Clinical-Surgical, Diagnostic and Pediatric Science; Dermatology Unit; University of Pavia; Fondazione IRCCS Policlinico San Matteo; Pavia Italy
| | - S.P. Cannavò
- Department of Clinical and Experimental Medicine-Unit of Dermatology; University of Messina; Messina Italy
| | - F. Guarneri
- Department of Clinical and Experimental Medicine-Unit of Dermatology; University of Messina; Messina Italy
| | - A. Cristaudo
- Department of Allergological and Occupational Dermatology; San Gallicano Dermatologic Institute, IRCCS; Rome Italy
| | - O. De Pità
- Laboratory of Immunology; Istituto Dermopatico dell'Immacolata (IDI)-IRCCS; Rome Italy
| | - R. Gallo
- Section of Dermatology; DISSAL - Department of Health Sciences; University of Genoa; Genoa Italy
| | - G. Girolomoni
- Department of Medicine; Section of Dermatology and Venereology; University of Verona; Verona Italy
| | - M. Gola
- Allergological and Occupational Dermatology Unit; Department of Critical Care Medicine and Surgery; University of Florence; Florence Italy
| | - P. Lisi
- Department of Medical and Surgical Specialities and Public Health; Section of Clinical, Allergological and Venereological Dermatology; University of Perugia; Perugia Italy
| | - P.D. Pigatto
- Department of Biomedical Science for Health IRCCS Galeazzi Hospital; University of Milan; Milan Italy
| | - R. Satta
- Institute of Dermatology; University of Sassari; Sassari Italy
| | - A. Giannetti
- Division of Dermatology; University of Modena and Reggio Emilia; Modena Italy
| | | |
Collapse
|
48
|
Zhang H, Goodman S, Yan R, Steg P, Kornder J, Gyenes G, Grondin F, Brieger D, DeYoung J, Gallo R, Yan A. IN-HOSPITAL MANAGEMENT AND OUTCOMES OF ACUTE CORONARY SYNDROMES IN RELATION TO PRIOR HISTORY OF HEART FAILURE. Can J Cardiol 2014. [DOI: 10.1016/j.cjca.2014.07.612] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022] Open
|
49
|
Sabbatini M, Vitale S, Garofalo G, Torino M, Gallo R, Carrano R, Federico S. Efficacy of subcutaneous epoetin-zeta on anemia in renal transplant recipients: a single-center experience. Transplant Proc 2014; 46:2238-40. [PMID: 25242760 DOI: 10.1016/j.transproceed.2014.07.027] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
BACKGROUND Persistent or "de novo" anemia (plasma hemoglobin<11 g/dL) may complicate the graft outcome in a significant number of renal transplant recipients. We describe a single-center experience with epoetin-zeta (EPO-Z), the biosimilar form for epoetin-alfa. METHODS Twenty patients were included in the study, 10 in treatment with different erythropoiesis-stimulating agents (ESA) and shifted to EPO-Z (shift group) and 10 who started EPO-Z treatment for anemia (naive group). All the patients had stable renal function and normal values of main inflammation markers and were prospectively followed up for 12 months. Iron supplements were administered during the study, as needed. RESULTS In the shift group, mean plasma hemoglobin levels>11 g/dL were maintained for the entire 1-year follow-up period, with average EPO-Z doses 3.4% higher than the corresponding doses of previous ESA; in the naive group, the target value was reached between the first and third months and remained stable throughout the study. Mean corpuscular volume did not vary in either group. No change was observed in glomerular filtration rate, nor in proteinuria or in main laboratory data. No drug-related side effect was reported. CONCLUSIONS EPO-Z may be considered a valid alternative to different ESAs in renal transplant recipients, with an interesting pharmaco-economic profile, considering its lower cost.
Collapse
Affiliation(s)
- M Sabbatini
- Renal Transplantation, Department of Public Health, University Federico II of Naples, Naples, Italy.
| | - S Vitale
- Renal Transplantation, Department of Public Health, University Federico II of Naples, Naples, Italy
| | - G Garofalo
- Renal Transplantation, Department of Public Health, University Federico II of Naples, Naples, Italy
| | - M Torino
- Renal Transplantation, Department of Public Health, University Federico II of Naples, Naples, Italy
| | - R Gallo
- Renal Transplantation, Department of Public Health, University Federico II of Naples, Naples, Italy
| | - R Carrano
- Renal Transplantation, Department of Public Health, University Federico II of Naples, Naples, Italy
| | - S Federico
- Renal Transplantation, Department of Public Health, University Federico II of Naples, Naples, Italy
| |
Collapse
|
50
|
L'Allier PL, Gallo R, Tanguay JF, Jolicoeur ME, Bonan R, Dorval JF. TCT-626 Expanding Indications of Bioresorbable Scaffolds: Single Center Procedural and In-Hospital Outcomes with the first 500 Implanted Devices in a Diversified, All-Comer Patient Population. J Am Coll Cardiol 2014. [DOI: 10.1016/j.jacc.2014.07.691] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|